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Introduction 
 
In this thesis we will discuss  antidepressant use in primary care, in particular long-
term (> 9 months) antidepressant use.  When this long-term antidepressant usage is 
not in line with the current professional standards, it can be categorized as 
inappropriate. In this thesis we will test an intervention to reduce this inappropriate 
long-term use of antidepressants. Inappropriate long-term antidepressant use can 
include under-treatment (requiring further treatment steps) and over-treatment 
(antidepressant is not (longer) needed). 
 
 
Primary care and the changing perspectives of depression and antidepressants’ use 
 
Most antidepressants are prescribed in primary care: 80% of all antidepressant 
prescriptions are written by General Practitioners (GPs) and antidepressants are one of 
the top five medications prescribed by GPs (1). Antidepressants are an evidence-based 
treatment for a number of psychiatric disorders, in particular depressive and anxiety 
disorders, as  described in clinical guidelines (2-6). Perceptions of the role of 
antidepressants in the treatment of a depressive disorder in primary care have 
changed over time. First, antidepressants were promoted as being the best available 
treatment for a major depressive disorder and not prescribing them to patients with a 
major depressive disorder was considered inappropriate. Under-treatment in primary 
care was frequently highlighted (7). Antidepressant treatment for patients with 
subthreshold depressive symptoms or dysthymia was also suggested (8). Psychological 
treatment was only recommended if patients were motivated and considered to be 
able to be self-reflective. The current guideline for GPs in the Netherlands has become 
more reserved concerning the prescription of antidepressants (6). Currently, the first 
course of action is to educate the patient, followed by watchful waiting and (short) 
psychological treatment options. When this fails or in case of severe symptoms, 
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antidepressants remain a treatment option.  Once antidepressants have been 
prescribed, the recommendation is to continue the use for 6 to 12 months after first 
adequate response, the duration differing slightly between guidelines (3, 4, 9). 
Maintenance therapy is recommended for patients with recurrent depression, with 
recurrent being defined as either 2 (4, 9) or 3 episodes (3). Patients with other risk 
factors for relapse, such as a family history of mood disorders, are also considered to 
possibly benefit from continued use (9). When symptoms do not improve after the first 
antidepressant, current guidelines recommend to change the antidepressant dosage or 
type, or to start psychological treatment. 
 
In this change of perspective on antidepressive treatment in primary care, patients and 
GPs have been caught in the middle. After the promotion of antidepressant use, now 
the same (but updated) evidence-based guidelines consider their prescriptions as 
possibly inappropriate. The research conducted in this thesis was performed during 
this dynamic change of perceptions of antidepressant usage and will be further 
addressed in the general discussion. 
 
 
Rise of antidepressant prescriptions  
 
The number of prescriptions of antidepressants has increased in the last two decades 
(figure 1). In particular, a substantial rise in the prescriptions of antidepressants took 
place after the introduction of the selective serotonin reuptake inhibitors (SSRIs) (10), 
with SSRIs still being the most prescribed antidepressant today (figure 2). In the last 
few years, the increase in antidepressant prescriptions has normalized to the average 
growth of medication use. Still, antidepressants rank 15
th
 on the list of most prescribed 
medications in the Netherlands, with 266 million defined daily doses in 2012 
(compared to 240 million in 2007) and one in every ten people use them today (1). 
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Figure 1. Antidepressant prescriptions in the Netherlands per year (1). 
 
The increase in antidepressant use could be explained by three factors:  
Prevalence, Recognition and Management. 
 
Prevalence 
An increase in prevalence of disorders that could be treated with antidepressants, 
could conceivably result in the increase of antidepressant use. However, a large meta-
analysis showed no change in prevalence of depressive and anxiety disorders over the 
past 2 decades, challenging the perceived epidemic of these mental health disorders 
(11). Also in the Netherlands, no significant change was found in the prevalence of 
these disorders (12). Thus, it seems that the prevalence does not play a large role in 
the increase in antidepressant prescriptions.  
 
Recognition 
 If the prevalence has not changed, may be the recognition of these disorders has 
improved and thus resulted in more and appropriate prescriptions of antidepressants. 
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Figure 2. Defined daily doses (DDD) of antidepressants in the Netherlands (1) 
 
In the past, primary care has been frequently criticized for not sufficiently recognizing 
patients with depressive and anxiety disorders (13-16). As a response, research and 
clinical projects have been set out to improve this, potentially causing the rise in 
antidepressant prescriptions. In psychiatric outpatient settings, depression is highly 
prevalent, whereas in primary care the prevalence is lower and there are more 
depression-like symptoms, sub-threshold depressive disorders and normal sadness 
(17).  In primary care, GPs have to balance between minimizing the number of false-
negatives and false-positives. Tools to diagnose disorders in psychiatry may be useful 
in primary care, in particular to prevent the under-recognition (18). But by improving 
the recognition, over-diagnosis can become an issue. Next to this, there still remains 
an ongoing discussion concerning the definition and criteria of depression in primary 
care (19, 20). Long-term course of depression in primary care has shown a different 
outcome, with less recurrence and lower mortality and suicide rates compared to 
psychiatric outpatient settings (21). 
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Management  
The rise in antidepressant use could also be the result of improved care: patients with 
a depression now receive the treatment needed. As the result of better compliance to 
guidelines, antidepressant treatment is continued for a longer period of time after a 
first positive response. Prescription-based studies have shown that the increase in 
total antidepressant prescriptions is due to continued use of antidepressants rather 
than more first prescriptions (22-26). Adherence to antidepressants in the acute phase 
of treatment has been proven difficult. Once this hurdle is overcome, however, 
evaluation of new SSRI users shows that one-third becomes a long-term user (25). The 
focus of this thesis lies on these long-term antidepressant users.  
 
 
Inappropriate long-term use of antidepressant  
 
Antidepressants can be prescribed inappropriately, i.e. not prescribed according to the 
guidelines or good clinical practice. Piek et. al. showed that in the Netherlands most 
initial antidepressant prescriptions are definitely or probably appropriate (54.5%  and 
40.1%, respectively).  Inappropriate prescriptions were mostly due to continuing 
antidepressants longer than needed (22). In a Scottish cross-sectional survey of long-
term repeat prescriptions of antidepressants, 57% failed to meet any psychiatric 
diagnosis on clinical assessment at the time of the survey and 31% had no clear clinical 
reason to continue, suggesting overtreatment (27).  
 
 
What is problematic about long-term use of antidepressants?  
 
In the case of under-treatment the problem of inappropriate long term use is 
apparent: patients still suffer from their psychiatric condition and should benefit from 
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further/other treatment. Patients suffering from depressive symptoms are more likely 
to accept suboptimal care (28) so, active engagement by their GP is essential.  
For the other group of inappropriate users, the overtreatment group, the problem 
might seem less clear. Effects of long-term use of antidepressants are poorly known. 
Weight gain and a higher risk for diabetes mellitus have been found associated with 
long-term antidepressant use (29). Recent research found that side effects of 
antidepressants known from short-term studies, persist during long-term use. Sixty-
four percent of antidepressant users reported an average of 3 side effects and the 
average prevalence of specific side effects ranged from 6% to 25%. At the top of the 
list: sleepiness, dry mouth and sexual dysfunction (30). Sexual dysfunction possibly 
persisting even after discontinuation of the antidepressant (31). Inappropriate long-
term use of antidepressants results in unnecessary exposure to these side effects.  
Antidepressants have become cheaper over time, with most patents being expired 
nowadays. Therefore direct costs of the medication do not play a large role as 
motivator to discourage inappropriate antidepressant usage. But with budget cuts and 
economic crises, every penny counts. Overtreatment with long-term antidepressant 
usage can also be counterproductive, as medication use may diminish patient 
empowerment while regaining control is considered essential for recovery (20).   
 
 
Scope of this thesis 
 
This thesis aims to provide insight in inappropriate long-term antidepressant use in 
primary care. 
We performed  a cluster randomized controlled clinical trial: the PANDA study. This 
study encompasses both issues concerning inappropriate antidepressant prescriptions, 
i.e. over- and under-treatment. In chapter 2 the design of the study is described in 
detail. The primary findings of the PANDA study are portrayed in chapter 3. In chapter 
4 we explore the cost effectiveness of the advice to discontinue long-term 
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antidepressants. Chapter 5 describes a qualitative study of the barriers and facilitators 
patients experience when discontinuing long-term antidepressant use. As the doctor-
patient relationship is the essence of general practice (32-34) and associated with 
patient improvement in mental health care (35), we conducted a systematic review of 
instruments available to assess the doctor-patient relationship (Chapter 6). All findings 
are summarized in chapter 7 and the results are discussed in chapter 8. 
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Abstract 
 
Background: Inappropriate use of antidepressants (AD), defined as either continuation 
in the absence of a proper indication or continuation despite the lack of therapeutic 
efficacy, applies to approximately half of all long term AD users. 
Methods/design: We have designed a cluster randomized controlled clinical trial to 
assess the (cost-) effectiveness of an antidepressant cessation advice in the absence of 
a proper indication for maintenance treatment with antidepressants in primary care. 
We will select all patients using antidepressants for over 9 months from 45 general 
practices. Patients will be diagnosed using the Composite International Diagnostic 
Interview (CIDI) version 3.0, extended with questions about the psychiatric history and 
previous treatment strategies. General practices will be randomized to either the 
intervention or the control group. In case of overtreatment, defined as the absence of 
a proper indication according to current guidelines, a cessation advice is given to the 
general practitioner. In the control groups no specific information is given. The primary 
outcome measure will be the proportion of patients that successfully discontinue their 
antidepressants at one-year follow-up. Secondary outcomes are dimensional measures 
of psychopathology and costs. 
Discussion: This study protocol provides a detailed overview of the design of the trial. 
Study results will be of importance for refining current guidelines. If the intervention is 
effective it can be used in managed care programs. 
Trial registration: NTR2032 
Keywords: Depression, Anxiety, Composite International Diagnostic Interview (CIDI), 
Randomized controlled trial, General practice, Depressive disorder, Anxiety disorders 
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Background 
 
Depressive- and anxiety disorders are among the most prevalent disorders, with 
lifetime prevalence rates of 19% for both (1). Most patients with depressive- and 
anxiety disorders are treated in general practice. In the last decade of the 20th 
century, prescription rates for antidepressants have increased 4 to 10 times in general 
practice (2,3). Currently, 2.1–2.5% of patients treated in primary care receive 
antidepressants for 9 months or longer, i.e. 50–60 patients per average Dutch general 
practice with 2350 patients (4). The appropriateness of long-term antidepressant 
usage is a matter of debate (5). From a patient perspective, inappropriate use of 
antidepressants has serious consequences for safety, wellbeing and daily functioning 
(5). Also there are negative side effects such as sexual disorder, emotional flattening, 
interaction with other drugs and sedation (6). From an economic perspective, 
inappropriate use of antidepressants is expensive considering the high costs of modern 
antidepressant drugs in the case of overtreatment and the high costs for productivity 
loss due to depressive and anxiety disorders in the case of undertreatment. Although 
the Dutch NEMESIS data show that half of the identified antidepressant drug users still 
suffered from a depressive or anxiety disorder (5) and are thus in need of subsequent 
treatment steps we considered this type of inappropriate treatment beyond the scope 
of the study reported here. 
 
Current guidelines advise to continue treatment with antidepressants for 6 months 
after remission for a first or second depressive episode or a successfully treated 
anxiety disorder, which means a total treatment duration of approximately 9 months 
(7,8). Overtreatment is therefore defined as the continued prescription of 
antidepressants without an appropriate indication at start or continued prescription 
during more than 6 months after remission of the index disorder. There is evidence of 
overtreatment in primary care. Antidepressants are often initiated during the first 
consultation with the general practitioner (GP) about emotional symptoms (9). 
Moreover, up to 80% of the users receive antidepressants for mild to moderate 
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depressions (4,10-12), while 60% of these depressions remit spontaneously within 6 
months (5). The Netherlands Mental Health Survey and Incidence Study, has shown 
that about half of the antidepressant drug users in the community did not meet the 
criteria for a depressive or anxiety disorder in the past six months. Similar results were 
found in chart review studies, showing that GPs had not registered a psychiatric 
diagnosis in nearly 40% of patients receiving prescriptions for antidepressant drugs. 
(3,4,13) Furthermore, 10–15% of long-term antidepressant drug users continue usage 
after remission without trying to discontinue it.  
 
Aim of the study  
The aim of this study is to reduce ‘overtreatment’, i.e. long-term use of 
antidepressants (>9 months) in the absence of an indication for maintenance 
treatment with antidepressants according to current guidelines. We will evaluate the 
(cost) effectiveness of a cessation advice to the general practitioner based on a 
detailed patient assessment in general practice. 
 
Study hypotheses 
The main hypothesis is that the intervention will lead to a higher reduction in 
antidepressant usage as well as lower (in)direct costs compared to the control  
condition. A second hypothesis is that these gains will be achieved without 
deterioration of psychological functioning. 
 
 
Methods/design 
 
Design of the trial 
This study consists of a randomized controlled parallel group trial, which will be 
conducted in general practice (see Figure 1 for an overview). Patients using 
antidepressants for at least nine months or longer are eligible for participation. 
208729-L-bw-Eveleigh
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Potentially eligible patients will be identified within the computerized prescription 
databases of the participating general practices. The GP will check the exclusion 
criteria (see below) for the patients on these generated lists. After a structured 
psychiatric interview using the Composite International Diagnostic Interview (CIDI) 3.0 
(14) with added detailed questions about psychiatric history and treatment, patients 
meeting the inclusion criteria will included in the trial. In case of under-treatment, i.e. 
the presence of a psychiatric diagnosis despite long-term antidepressant usage, 
patients will be offered to participate in a second trial that will be conducted in 
tandem (see trial registration database: NTR2032). As we failed to recruit a sufficient 
number of patients for this second trial, no further details will be given here. 
 
The primary outcome measure is successful discontinuation of antidepressant drug 
use, defined as no use of antidepressants during the 6–12 month follow-up in the 
absence of a psychiatric disorder. At the 12-month follow-up, the CIDI 3.0 will be re-
administered by an interviewer blind for baseline results. Secondary outcome 
measures include a detailed set of dimensional measures of psychopathology, quality 
of life and costs (see below) administered at baseline and at 3, 6, 9, and 12 months 
follow-up (see below). 
 
Setting 
The study will be conducted in general practice. Between February 2010 and January 
2012, a total of 56 general practices were contacted for participation of which 45 
practices (response rate 80.3%) have actually participated in the study: 31 practices 
from the Primary Care Network of the Radboud University Nijmegen Medical Centre 
and 14 practices not connected with this network. 
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Figure 1 Study flowchart cluster randomisation. (*informed consent will be asked for a 
randomised controlled trial in tandem to improve 'undertreatment' in long-term antidepressant 
users. Abbreviations: GP, general practitioner; CIDI, Composite International Diagnostic 
Interview) 
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Patients 
Eligibility assessment 
Patient recruitment took place between May 2010 and May 2012. General 
practitioners systematically identified all users of antidepressants using the 
prescription records of their electronic medical records (supported by our research 
team). However, GPs were able to exclude long-term users a priori based on the 
exclusion criteria (known to them) or specific reasons that had to be specified per 
patient. All remaining patients using antidepressants for over nine months were 
considered eligible and received written information about the study. Those who 
consented to participate were contacted by the researcher for further information and 
screened once more on the in- and exclusion criteria. Patients who still met the criteria 
received a formal appointment for structured psychiatric interview by telephone using 
the Composite International Diagnostic Interview, version 3.0 (CIDI 3.0). 
 
Inclusion criteria 
1. Having received prescriptions for antidepressants for at least nine months in an 
amount sufficient for at least 270 days of use according to the prescribed dosage 
extracted from the electronic prescription records. Except for MAO-inhibitors, all types 
of antidepressants are included in this study. We do not include patients who receive 
MAO-inhibitors because these drugs can only be prescribed by psychiatrists in the 
Netherlands. 
2. Having given written informed consent before the date of the psychiatric interview. 
 
Exclusion criteria 
1. Appropriate use of long-term antidepressants according to the Dutch guidelines for 
depressive and anxiety disorders, i.e. a) a history of recurrent depression with 3 or 
more episodes and/or a recurrent psychiatric disorder with at least two relapses after 
antidepressant-discontinuation. 
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2. Presence of a current psychiatric diagnosis for which antidepressants may be  
effective, i.e. depressive disorder, dysthymia, generalized anxiety disorder, panic 
disorder, or social phobia); 
3. Current treatment in a psychiatric setting; 
4. History of psychosis, bipolar disorder, or obsessive compulsive disorder; 
5. Current diagnosis of substance use disorder; 
6. Non-psychiatric indication for long-term antidepressant usage, e.g. neuropathic 
pain; 
7. Inability to perform the necessary assessment due to a hearing impairment  
(telephonic interview) and/or no understanding of the Dutch language (telephonic 
interview and survey). 
 
A total number of 146 patients have been included. The one-year follow up interviews 
have started in May 2011 and are still going on, expectedly till May 2013. 
 
Randomization 
To prevent contamination between intervention and control group a cluster 
randomization is performed with the general practice as the unit of clustering. Random 
assignment was insured by picking a sealed envelope with intervention or control 
group after patient recruitment had been concluded in that particular practice. The 
cessation advices will only be sent to the GPs from practices allocated to the 
intervention group. GPs from practices in the control group are asked to continue their 
usual care, as if they were not participating in this trial. Interviewers who conducted 
the baseline and follow-up interviews as well as the psychiatrist and general 
practitioner who judged the indication of maintenance treatment will remain blinded 
throughout the trial. 
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Intervention 
The intervention implies the discontinuation of antidepressant use, following the 
recommendations in the Dutch multidisciplinary guidelines for depressive and anxiety 
disorders (15). These are similar to those in the British NICE guidelines, recommending 
strict indications for the initiation, continuation and discontinuation of antidepressants 
(7). Although in a recent meta-analysis patients with a single depressive episode 
showed no difference in relapse rates between abrupt and gradual antidepressant 
discontinuation (16), we advised a gradual tapering program for the following reasons: 
1) abrupt discontinuation may trigger a relapse in patients who suffered from an 
anxiety disorder or a recurrent depressive disorder at the time of initiating the 
antidepressant (16), and 2) discontinuation symptoms occur more frequently in 
patients who abruptly discontinue their antidepressants than in patients whose 
treatment is gradually tapered (17,18). The general practitioner receives a letter 
stating that the patient does not meet the criteria for a depressive or anxiety disorder 
in the past six months. In addition, he or she receives an information sheet with 
current guidelines on antidepressant tapering and information about the 
discontinuation syndrome (19), including a detailed scheme for tapering for each 
patient (see Table 1). Duration of tapering was primarily based on the dosage and the 
half-life of the different antidepressants. No treatment restrictions are imposed on GP 
or patient in case of relapse or onset of a new psychiatric disorder after  detailed 
information and a treatment algorithm for all depressive and anxiety disorders. In a 
case of incongruent advices the psychiatrist and the general practitioner will discuss 
the case until they reach consensus. Incongruence between the GP and psychiatrist 
will be reported as percentage disagreement.  
 
To check the reliability of the proposals by the GP and psychiatrist, we provided 
another GP (CvW) and psychiatrist (AS) with 10 randomly selected case vignettes from 
included patients. Comparing these judgments, there was a 100% agreement. 
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Control condition 
The control condition will consist of usual care and do not impose restrictions on GPs 
to deliver care or to refer to specialized mental health care, including the continuation 
or discontinuation of psychotropic drugs. Since baseline psychiatric diagnostics will not 
be disclosed for patients who have given informed consent in a control practice (also 
those with appropriate use or under-treatment), we expect continuation of 
antidepressant drug treatment in most cases (13). 
 
 
 
Table 1. Applied schemes for tapering long-term antidepressant usage in primary care 
Antidepressant AD tapering scheme (steps per 2 weeks, dose in mg/day) 
 Start dose Step 1 Step 2 Step 3 Step 4 
TCA      
  Amitriptyline  > 150 150 100 50 25 
  Imipramine  > 150 150 100 50 25 
  Nortriptyline  > 150 150 100 50 25 
  Clomipramine  > 150 150 100 50 25 
SSRI      
  Fluoxetine > 60 40 30 20 10 
  Paroxetine > 40 40 30 20 10 
  Sertraline  > 150 150 100 50 25 
  Citalopram > 40 40 30 20 10 
  Escitalopram > 20 20 15 10 5 
  Fluvoxamine  > 150 150 100 50 25 
Other 
antidepressants 
     
  Duloxetine  > 120 120 90 60 30 
  Venlafaxine   > 150 150 112.5 75 37.5 
  Mirtazapine > 45 45 30 15 - 
  Trazodon  > 150 150 100 50 - 
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Assessments 
Eligible patients who consent for participation will receive a psychiatric interview by 
telephone, using the depression and anxiety part of the Composite International 
Diagnostic Interview (CIDI) (20,21) as well as the sections on social phobia, bipolar 
disorder, generalized anxiety disorder, neurasthenia, specific phobia and obsessive 
compulsive disorder. The CIDI is a structured and fully standardized psychiatric 
interview for diagnosing mental disorders according to ICD and DSMIV criteria. 
The CIDI interview can be done by trained laymen, and thus imposes no restrictions on 
the interviewers. Furthermore, telephonic administration of the CIDI has been 
demonstrated feasible and reliably (20,21). To enable the preparation of treatment 
proposal, the CIDI interview was extended with detailed questions about previously 
used psychotropic drugs (duration and dosages) and psychosocial therapies. In case of 
psychotherapy, predefined questions were asked to discern between cognitive-
behavioural interventions, interpersonal therapy and/or structured/supportive 
therapy. In addition, demographic variables, the use of psychoactive substances 
(nicotine, alcohol, and drugs), screening of posttraumatic stress disorder, and the 
presence of chronic somatic disorders will be recorded at the baseline interview. The 
CIDI 3.0 interview will be repeated after one year follow-up. Subsequently, all patients 
will fill out a set of self-report questionnaires at baseline and at 3, 6, 9 and 12 months 
follow-up (see secondary outcome measures below). Personality characteristics and 
the quality of the patient-physician relationship have been suggested to affect 
treatment outcome of common mental disorders in primary care. Therefore, these 
characteristics will be examined additionally at baseline by administration of the NEO-
Five Factor Inventory (NEO-FFI) (22) and the Patient Doctor Relation questionnaire 
(PDRQ) (23). 
 
Primary outcome measures 
The primary outcome is the proportion of participants who successfully discontinue 
their long-term antidepressive drug use. This is defined as having no antidepressant 
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drug use within the last 6 months of the follow-up and the absence of a depressive or 
anxiety disorder during one-year follow-up as assessed with the CIDI 3.0. Use of 
antidepressants will be evaluated with questions during this second CIDI interview as 
well as with self-report questionnaires. In case of inconsistencies between both 
measures, the patient will be re-contacted and if necessary the GP will be contacted to 
check the GP prescription database. This latter solution is considered reliable as in the 
Netherlands all patients are linked to only one GP who collects all medical information 
for that patient. 
 
Secondary outcome measures 
Secondary outcome measures are the severity of psychological symptoms, quality of 
life, costs and also the prevalence of discontinuation symptoms. We have only 
included self-report questionnaires that are validated in Dutch and have shown good 
to excellent psychometric properties. The overall severity of psychological distress and 
global psychopathology will be based on the Brief Symptom Inventory (BSI-53) sum 
score. The BSI-53 is a shortened version of the Symptom Checklist (SCL) 90-item 
version (24) with similar psychometric characteristics and subscales, but less patient 
burden (25). For more detailed evaluation, we also included disorder specific 
instruments: 
– The Centre for Epidemiological Studies Depression Scale (CES-D) for measuring the 
severity depressive symptoms (26); 
– The Penn State Worry Questionnaire (PSWQ) for assessing the frequency and 
severity of symptoms of worrying (27); 
– The Panic and Agoraphobic Scale (PAS) for measuring the severity of illness in 
patients with panic disorder (28); 
– The Fear of Negative Evaluation Scale (FNES) for assessing expectations and distress 
associated with negative evaluations by others (29); 
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The EuroQol-5D (EQ-5D) offers the possibility to evaluate effects of quality of life, 
although this questionnaire is primarily included to enable the economic analyses by 
providing a utility score (30-33). The EQ-5D has previously been validated and has been 
applied successfully in studies of depressive and anxiety disorders. Costs will be 
measured by the Trimbos/iMTA questionnaire for Costs associated with Psychiatric 
Illness (TiC-P) (34). Finally, the prevalence and severity of an antidepressant 
discontinuation syndrome will be measured in those who withdraw from medication 
using the Discontinuation-Emergent Signs and Symptoms (DESS) Scale (35). This latter 
scale, however, has not been validated in Dutch. 
 
Power 
A senior academic statistician using SAS POWER procedure performed a prospective 
sample size calculation. It aimed to determine a target sample size that would provide 
at least 85% power for two-tailed testing (at a type-1 error rate of 5%). Because our 
trial is cluster randomized, calculations to determine the minimum number of general 
practices is stricter than in a non-clustered trial. To account for this, we used an intra-
class correlation (ICC) of 0.05. Assumptions with respect to recruitment and outcome 
are difficult to estimate. We expect a 20% discontinuation rate for patients in the 
control group, and a 50% discontinuation rate in the intervention group. The 20% 
discontinuation rate is conservatively estimated (probably lower than 20%) based on 
the fact that in the Netherlands, the rate of spontaneous non-adherence to 
antidepressant drug therapy has been estimated at 25% within the first 6 months (36). 
This rate is expected to decline gradually as the treatment time elapses (as those 
patients with initial side-effects have already dropped out). The 50% discontinuation 
rate is based on the results of a primary care benzodiazepine discontinuation study of 
our group (37,38). This number is also considered conservative, as in contrast to 
benzodiazepines, psychological dependency does not play a major role in long-term 
use of antidepressants. The recruitment rate was originally based on a small qualitative 
pilot study assuming that one average general practice would enable to include 6 
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patients in the trial. Assuming a dropout rate of 25%, a total of 20 practices (160 
patients) had to be recruited. As the number of patients recruited per practice was 
lower than expected, we recruited more practices for participation in the study. A total 
of 45 practices finally participated in the study, which resulted in the recruitment of 
146 patients. Based on our a priori assumptions of the success rates and dropout rates, 
we will have over 85% power. 
 
 
Data analysis and treatment effect 
 
Descriptive statistics 
The trial has a binary primary outcome, i.e. successful discontinuation yes or no, and 
dimensional secondary outcome parameters. In order to check for baseline differences 
between the two groups, a series of univariate analyses (t-tests, chi-square tests, 
Mann–Whitney tests) on psychiatric status and demographic variables will be 
performed. 
 
Multilevel analysis 
Multilevel analyses will be used to account for the hierarchical structure of the data 
(i.e. patients nested within practices). Covariates (see above) will be included if they 
show a relationship with the outcome. The secondary outcome measures (continuous 
variables) will be analysed by using the mixed procedure in SAS. Firstly, a general 
comparison will be made based on the BSI-53 (general distress), which is applicable to 
all patients. Secondly, disease-specific instruments will be pooled after having 
determined the most relevant disease-specific questionnaire for each patient based on 
one’s primary diagnosis assessed with the CIDI at study entry (i.e. depressive disorder, 
panic disorder, generalized anxiety disorder or social phobia). The scores on the 
different questionnaires will be transformed into standardized t-scores, in order to 
pool these data in multilevel analysis for continuous variables. In case the CIDI at 
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baseline will not identify any psychiatric disorder for which the antidepressant drug 
treatment has been initiated, the BSI-53 score will be taken. 
All analyses will be performed on an intention-to-treat basis. Patients who dropped 
out will be classified as failure (for the primary outcome variables). For the secondary 
outcome measures, missing values will be imputed by multiple imputation techniques. 
 
Interim analysis 
The investigators do not expect any serious adverse events that will require an interim 
analysis to make a deliberate consideration of terminating the study earlier than 
planned (approved by the institutional ethics committee). Due to the statistical 
characteristics of an interim analysis, the achieved power of this study would 
be unnecessarily reduced. 
 
Ethical aspects 
The trial is registered before start of the study, and will be reported according to 
CONSORT guidelines. Our study is approved by the institutional ethics committee 
Nijmegen under registration number NL29718.091.09 and registered in the 
Netherlands Trial Register NTR2032. 
Informed consent is obtained from the subjects before entering the study. Before 
patients give their consent, a detailed information package is sent to them, which 
provides the aims and characteristics of the study. All subjects are informed that 
participation in the study is voluntary and that they are allowed to withdraw from 
the study at any time. 
 
Discussion 
 
We have described the study protocol of a cluster randomized controlled clinical trial 
to evaluate the impact of cessation advice to the GP in order to reduce overtreatment 
with antidepressants in general practice. The primary outcome measure is the 
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proportion of patients that successfully discontinued their antidepressants. Secondary 
outcomes include dimensional measures of psychopathology and (in)direct costs.  
 
Cluster randomization 
We applied cluster randomization instead of individual or normal randomization for 
two reasons (39). Firstly, randomization at the patient level would inevitably have led 
to contamination, as receiving cessation proposals for some, but not all patients 
included from an individual GP, would inevitably trigger him or her to rethink their 
strategy of control patients. During the trial, treatment given to control patients will 
probably be contaminated. Secondly, in our study the patients are nested in general 
practices and cannot be considered as statistically independent. Thus, when not taking 
into account the general practice as unit of cluster, this will inflate type I errors (40). 
 
Generalizability 
The study is based on a pilot study, performed before the PANDA study started. In this 
pilot study there was a calculation made how many patients were using 
antidepressants for more than 9 months. We identified significantly fewer patients per 
general practice/general practitioner who participated in the study. This might limit 
the generalizability of our findings. Because of this finding we performed some 
recalculations of the power analysis (as described above). This is not necessarily 
problematic, since including fewer patients per practice will improve the power. 
Furthermore, being a primary care study, we cannot generalize our results to those 
patients treated in psychiatric care. Overtreatment is probably also an issue in 
specialized mental health care, although to our knowledge of exact figures are lacking. 
We excluded patients under current treatment in a psychiatric setting to prevent 
interfering with current specialized treatment. Nonetheless, most patients suffering 
from anxiety and/ or depressive disorders are treated in primary care (41). 
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Two trials in tandem 
Classifying long-term users of antidepressants as being undertreated or over-treated 
requires a full psychiatric diagnostic work-up. The necessity and investment of this 
psychiatric work-up has led to the decision to conduct two trials in tandem using one 
recruitment strategy. Although available data suggested comparable proportions of 
patients being over- or undertreated, reality was hard-hearted. Recruitment rates in 
both trials were a little disappointing, but for the trial described in this paper we could 
include sufficient patients to achieve over 85% power based on a priori effect-sizes by 
recruiting more general practitioners to participate in our project. Nonetheless, we 
failed in recruiting sufficient patients for second trial aimed to improve under-
treatment, i.e. the presence of psychiatric disorder despite the use of an 
antidepressant (which argues for further treatment steps in primary care). If not 
conducted in tandem, recruitment strategies for this second trial that was conducted 
parallel to the trial presented could have been elaborated, as done in many other 
randomised controlled trials facing recruitment problems. We thus have to conclude 
that our planned efficiency appeared to be inefficient. 
 
Treatment proposals 
A psychiatrist and general practitioner made the cessation proposals independent of 
each other. The main decision for the present study was to determine whether 
patients received the antidepressants appropriately and if not, whether cessation 
should be recommended according to actual guidelines (in case of over-treatment) or 
further treatment steps should be taken to augment or change the treatment. 
Interestingly, the reliability of the treatment proposals was excellent, as shown by a 
100% agreement between the results of the second psychiatric-GP couple on 10 
randomly chosen patients.  
 
Clinical relevance of this trial (for update of guidelines) 
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This study aimed to answer questions on the (cost) effectiveness to taper 
antidepressant use in patients who have no recent diagnosis of depression and/or 
anxiety. These results will inevitably impact on the current guidelines. In case of non-
discontinuation, more emphasis should be paid on strategies to discontinue 
antidepressants in primary care. In case of high relapse rates after discontinuation, 
guidelines should be adapted regarding the duration of maintenance treatment. 
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Abstract 
Background: Antidepressant use has increased exponentially, mostly due to long 
continuation. Not all long-term usage is appropriate. 
Objective: To assess the effectiveness of a patient-and-psychiatric-diagnosis tailored 
recommendation to cease or adjust antidepressant treatment. 
Methods:  Two cluster-randomized controlled trials (PANDA-study) in primary care. 
Long-term antidepressant users (>9 months) were selected. Patients were diagnosed 
with the Composite International Diagnostic Interview 3.0. Long term users were split 
up in patients without an indication for maintenance treatment (over-treatment trial) 
and patients with a current diagnosis, despite maintenance treatment (under-
treatment). The intervention consisted of disclosure of the current psychiatric 
diagnosis combined with a (patient-tailored) treatment recommendation. Primary 
outcome in the over-treatment trial was the proportion who successfully discontinued 
antidepressant use at 1 year follow up. In the under-treatment trial this was remission 
after 12 months. 
Results: We included 146 participants from 45 family practices in the overtreatment 
trial. 70 patients received the recommendation to discontinue, 76 were allocated to 
the control group. Only 36 (51%, 95%CI 40-63) patients in the intervention group 
intended to comply with the recommendation. The proportion of successful 
antidepressant discontinuation did not differ (n=4; 6%, 95%CI 2-14 vs. n=6, 8%, 95%CI 
4-16). We included 58 patients the under-treatment study; remission was equal in 
both groups (n=13; 45%, 95%CI 28-62). 
Conclusion: This study demonstrates the difficulty of changing inappropriate long-term 
antidepressant treatment. A minimal intervention does not lead to less inappropriate 
long-term antidepressant use, with patients and general practitioners being 
apprehensive to change. 
Keywords (MESH): antidepressant agents, primary health care, depressive disorder, 
anxiety disorder, general practice, inappropriate prescribing 
Trial Register: NTR2032. 
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Introduction 
 
During the 1990’s antidepressants were promoted widely and general practitioners 
(GPs)  were criticized for under-diagnosing and under-treating depressive and anxiety 
disorders (1-3). Efforts were made to increase quality of care and prescription rates for 
antidepressants increased (4).  
 
Now, contrary concerns are raised concerning over-treatment with antidepressants 
(5). Long-term continuation contributes to the large amount of antidepressant use (6-
10). Studies suggest that many long-term users are exposed to antidepressants 
unnecessarily.(8, 11, 12) One-third of long-term antidepressant users have been found 
to have no identifiable justification (12). Also, a lack of medication review during the 
continuation of antidepressant treatment has been suggested (8). Clinical guidelines 
recommend to limit the duration of antidepressants to 6 months after remission for a 
first or second depressive episode or a successfully treated anxiety disorder.(13-16) 
 
Over-treatment with antidepressants is troublesome.  The effectiveness is 
questionable: about 5 of every 6 antidepressant users do not benefit (17).  From the 
GPs perspective, it is important to discuss how patients can use their own resources to 
cope with their problems;  providing medication might be counterproductive, as 
medication use may diminish patient empowerment while regaining control is 
considered essential for recovery (18).  
 
Under-treatment has been found to be 80% during the continuation or maintenance 
phase (19). More than half of patients treated with antidepressants in primary care 
receive doses smaller than recommended (20). Clinical guidelines recommend 
subsequent treatment steps in case of no response to improve wellbeing and to 
prevent a chronic course (14-17). 
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This study aims to reduce inappropriate long-term antidepressant use in general 
practice. We will evaluate the effectiveness of a patient-and-psychiatric-diagnosis 
tailored recommendation to cease (over-treatment) or adjust (under-treatment)  
antidepressant treatment.  
 
 
Methods 
 
We conducted two cluster randomised controlled trials in primary care in tandem. The 
study protocol is published elsewhere (21).   
 
Selection of study subjects 
The study was conducted in 45 general practices in the Netherlands between February 
2010 and March 2013. GPs identified long-term antidepressant users in their 
prescription database. GPs excluded patients based on the exclusion criteria below. 
We contacted consenting patients and checked in- and exclusion criteria. Eligible 
patients underwent a structured psychiatric interview by telephone using the 
Composite International Diagnostic Interview, version 3.0 (CIDI) conducted by trained 
interviewers (22-25). Patients without a current psychiatric diagnosis or another 
indication for continued use were allocated to the ‘over-treatment’ trial. Patients with 
a current (past 6 months) psychiatric diagnosis despite their long-term antidepressant 
use were allocated to the ‘under-treatment’ trial.  
 
Inclusion criteria:  
a) Long-term antidepressant use (≥9 months). All antidepressants were included, 
except MAO-inhibitors. 
b) Written informed consent. 
Exclusion criteria: 
a) Current treatment in a psychiatric in- or outpatient clinic;  
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b) Appropriate use of long-term antidepressants according to the Dutch guidelines 
for depressive and anxiety disorders (i.e. a history of recurrent depression (≥3 
episodes) and/or a recurrent psychiatric disorder with at least two relapses after 
antidepressant discontinuation);  
c) History of psychosis, bipolar disorder, or obsessive compulsive disorder; 
d) Current diagnosis of substance use disorder (excluding tobacco); 
e) Non-psychiatric indication for long-term antidepressant usage, e.g. neuropathic 
pain; 
f) Hearing impairment and/or insufficient understanding of the Dutch language. 
 
Over-treatment trial 
 
Intervention: a patient-specific letter was sent to the GP with the recommendation to 
discontinue the antidepressant. We provided information on antidepressant tapering 
and the discontinuation syndrome. We advised a gradual tapering program (21). The 
GP invited the patient to discuss the recommendation. No treatment restrictions were 
imposed in case of a relapse or onset of a new psychiatric disorder after 
discontinuation. A return slip was included, to ascertain the intention to comply with 
the recommendation. When either the GP or the patient did not intend to comply, we 
asked for the reasons. In the control group, GPs were unaware which patients 
participated in this study and continued usual care. 
 
Primary outcome: the proportion of participants who successfully discontinued their 
long-term antidepressant use after 1 year. This was defined as no antidepressant use 
during the preceding 6 months and the absence of a depressive or anxiety disorder 
during the one year follow up, as assessed by the CIDI. Medication use was collected in 
the follow up CIDI, as well as in self report questionnaires. Missing and contradicting 
prescriptions were checked by contacting the GP. Missing psychiatric diagnoses at 
follow up were estimated from the self report questionnaires at 12 months.  
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Secondary outcome: severity of general distress and depressive symptoms were 
assessed by the Brief Symptom Inventory (BSI-53) (26), and the Centre for 
Epidemiological Studies Depression Scale (CESD) (27), at baseline and after 3, 6, 9 and 
12 months follow up. 
 
Power analysis: our prospective sample size calculation aimed to provide at least 85% 
power for two-tailed testing with a type-1 error rate of 5 %. To account for the cluster-
randomisation, we used an intra-class correlation of 0.05. Assumptions with respect to 
recruitment and outcomes were difficult to estimate. We expected a 20% 
discontinuation rate for the control and 50% for the intervention group. Spontaneous 
non-adherence to antidepressants is found to be 25% (28), we expected this rate to 
decline as treatment time elapses. The expected discontinuation rate in the 
intervention group is based a primary care benzodiazepines discontinuation study (29, 
30). In an average Dutch general practice (2400 patients) has approximately 50-60 
patients using antidepressants long-term (31), with one-third possibly inappropriately 
(8). Our recruitment rate was also based on a small pilot study with 3 general practices 
being able to include 3 patients per practice. Assuming a drop-out rate of 25%, the 
required sample size calculated 34 practices and 136 patients. 
 
Statistical analyses: Analyses were conducted in IBM SPSS Statistics 20. Outcome 
analyses were performed on an intention-to-treat basis. Patients with an unknown 
primary outcome were classified as failure. The secondary outcome measures were 
analysed using a mixed models procedure for repeated measures, thus accounting for 
any missing values. 
 
Under-treatment trial 
 
Intervention: disclosure of the current psychiatric diagnosis combined with a patient-
tailored treatment recommendation based on the Dutch Multidisciplinary Guidelines 
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for the treatment of depressive disorder and of anxiety disorders (18, 19). Compliance 
was ascertained, and in the control group GPs continued their usual care.  
 
Primary outcome: the proportion of participants in which the depressive or anxiety 
disorder at baseline had remitted at one-year follow-up (based on the CIDI).  
 
Secondary outcome: the severity of psychological symptoms, assessed by self-report 
questionnaires at baseline and after 3, 6, 9, and 12 months. The overall severity of 
psychological distress and global psychopathology was based on the Brief Symptom 
Inventory (BSI-53) (26). We also included disorder specific instruments: the Centre for 
Epidemiological Studies Depression Scale (CES-D) (32); the Penn State Worry 
Questionnaire (PSWQ) (33); the Panic and Agoraphobic Scale (PAS) (34); the Fear of 
Negative Evaluation Scale (FNES) (35).  
 
Analyses: an intention-to-treat basis, with patients lost to follow up classified as failure 
(for the primary outcome). Information from the questionnaire at 1 year follow up was 
used to estimate the primary outcome when missing. Secondary outcome measures 
were analysed using mixed models procedure. First, the mean BSI-53 score was 
analysed. Secondly, disease-specific instruments were pooled, after having determined 
the most relevant disease-specific questionnaire for each patient based on one’s 
primary diagnosis assessed with the CIDI at study entry, and transformed into 
standardized T-scores. In case of missing values, the BSI-53 score was taken. 
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Figure 1. Flow diagram of practices and participants.    
*post-randomization patients did not meet inclusion 
criteria 
†patients who did not complete follow up interview 
‡ patients excluded with unknown primary outcome  
§ intervention group restricted to patients with the 
intention to comply to recommendation and patients 
excluded with unknown primary outcome. 
 
*post-randomization patients did not meet inclusion 
criteria 
†patients who did not complete follow up interview 
‡ patients excluded with unknown primary outcome  
§ intervention group restricted to patients with the 
intention to comply to recommendation and patients 
excluded with unknown pri ary outcome. 
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Results 
 
Over-treatment trial 
 
Forty-five practices participated. In total, 6442 long-term antidepressant users were 
identified, of whom 2411 (37%) were deemed eligible by their GP. 358 (15%) patients 
consented to participate and 146 were included in this study (figure 1). 
 
Study population 
Patient characteristics were well balanced at randomization (table 1). Figure 2 shows 
the distribution of patients and their outcomes. 
In almost half of the cases the recommendation to discontinue was rejected (n=34/70; 
48%, 95%CI 37-60): by the patient in 14 cases (41%), the GP in one (3%) and as a 
shared decision in 16 (47%). Reasons for rejecting the recommendation: fear of 
recurrence (n=19, 56%), relapse after previous discontinuation (n=4, 12%), presence of 
psychological symptoms (n= 5, 15%), wanting a second opinion (n=4, 12%) and other 
reasons (unspecified) (n=2, 6%). 
General distress or depressive symptoms at three months (approximately the time of 
consultation with GP to discuss the given recommendation) were not predictive for 
acceptance of the recommendation to discontinue (mean BSI 0.4, 95%CI 0.2 to 0.5; 
mean CESD 17, 95%CI 13-21 vs. mean BSI 0.4, 95%CI 0.2-0.6; mean CESD 15, 95%CI 11-
18).  
 
Primary outcome 
In the intervention group four patients (6%, 95%CI 2-14) successfully discontinued 
their antidepressant, in comparison to six patients (8%, 95%CI 4-16) in the control 
group. When combining the intervention and control groups, we found successful 
discontinuation of antidepressant use in 10 patients (7%, 95%CI 4-12). 
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Secondary outcomes 
We found a significantly higher relapse rate in the intervention group (n=18; 36%, 
95%CI 25-50) compared to the control group (n=10; 14%, (95%CI 8-25) (p=0.015). This 
difference was not associated with antidepressant discontinuation. Comparison of 
patients who continued their antidepressants, did yield a significantly higher relapse 
rate in the intervention versus control group (36%, 95%CI 23-52 vs. 13%, 95%CI 6-24, 
p=0.02). 
Patients who successfully discontinued their antidepressant did not differ from the rest 
of the study population in gender, age, type of antidepressant used (SSRI, TCA or 
other) or psychiatric diagnosis. However, the mean duration of AD use appeared to 
trend toward a shorter duration in patients who successfully discontinued their AD (5.7 
years; 95%CI 1.6-9.7 years vs. 9.6 years (95%CI 8.3-11.0 years), p=0.077). 
 
Under-treatment trial  
 
Study population 
Fifty-eight patients were included in the under-treatment  trial (figure 1 and table 1). 
Of the 29 treatment recommendations, five (17%, 95%CI 7-36) were medication 
recommendations, eight (28%, 95%CI 14-46) psychological and 16 (55%, 95%CI 4-7) 
consisted of a choice between both. Twelve (41%, 95%CI 25-60) patients intended to 
comply with the recommendation. The decision to reject the recommendation was 
shared by the GP in nine cases (53%).  
 
Primary and secondary outcomes 
The proportion of patients achieving remission of their psychiatric disorder was exactly 
the same in the intervention and the control group: 45% (95%CI 28-62). Additionally, 
we found no significant difference in trend on the severity of general distress between 
the intervention and control group in the longitudinal data during follow up, nor in the 
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pooled T-scores for the disease specific questionnaires. There were no significant 
baseline differences between the two groups.  
 
 
Discussion 
 
Over-treatment trial 
This study shows the difficulty of discontinuing inappropriate long-term antidepressant 
use. Irrespective of the condition patients were allocated to, only 10 of the 146 
patients with inappropriate long-term use of antidepressants were able to successfully 
stop in the year of the study. Half of the patients in this study rejected the 
recommendation to discontinue. Even when intending to comply, more than half 
(56%) eventually did not. Interestingly, the number of patients spontaneously 
discontinuing their antidepressant was similar to patients receiving the 
recommendation.  
  
The studied intervention was based on previous experiences with discontinuation of 
long-term benzodiazepine use, were a stepped care approach has been found effective 
(36). A minimal intervention, consisting of an advisory letter or a consult to discuss 
discontinuation with the GP proved effective to discontinue benzodiazepines (37). 
Apparently the parallel with antidepressants was made too easily, with patients and 
GPs being reluctant to discontinue. 
 
Qualitative research has suggested that patients attribute their wellbeing to the 
(continued) use of antidepressants and are more afraid of stopping than of continuing, 
i.e. “better safe than sorry” (38, 39). They believe their condition to be chronic and 
requiring life-long treatment, while feeling uncomfortable with this prospect (38-40). 
Barriers GPs perceive include: concerns “not to disturb the ‘equilibrium’ the patient 
experiences”, “follow the path of least resistance” and, “let patients be”(40). There 
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seems to be a conflict between the application of guidelines versus taking the 
dynamics of the clinical encounter into account. So the question arises: does the GP 
dismiss the guideline inappropriately, or is the guideline inappropriate (41)? 
 
We found a significantly higher relapse rate in the intervention group. Strikingly, this 
was not associated with antidepressant discontinuation. The focus on the 
antidepressant use could have caused a higher risk of relapse, patients could have felt 
obliged to act upon this recommendation without an internal motivation, causing 
more anxiety for relapse and consequently, due to higher anxiety levels, a higher risk 
of relapse. In addition, possibly feelings of failure could arise when rejecting the 
recommendation.  
 
 
Under-treatment trial 
We found a low number of patients being under-treated amongst the participating 
long-term antidepressant users in primary care, in contrast with the literature (19, 42, 
43). This could suggest that the prevalence is low, but could also be the result of a 
failed recruitment and selection bias. Eventhough we were unable to recruit sufficient 
patients for the under-treatment trial to reach  adequate power (21), we feel that the 
results of this study are important to discuss. 
The results of the under-treatment trial showed that providing GPs with a patient-
tailored treatment recommendation did not have any beneficial effect on remission 
rates in patients suffering from a current depressive or anxiety disorder despite long-
term use of antidepressant medication. Not unsurprisingly, as more than half of the 
patients (and their GPs) were unwilling to accept the given recommendation. 
Patient preference has been emphasized to be of great importance in treating 
depressive disorders (44). The rejection of the recommendation was mostly driven by 
an apprehension to change. Maybe for these patients there is no necessity of 
remission and taking long-term antidepressants is ‘good enough’. Despite that studies 
208729-L-bw-Eveleigh
Prescribing Antidepressant Appropriately 
 
53 
have shown that remission is consistently associated with a better prognosis than 
symptomatic improvement without full remission of the disorder (45), it is conceivable 
that for patients the treatment goal is not remission, but merely symptom alleviation.  
 
 
Study limitations 
To our knowledge this is the first randomized controlled clinical trial focusing on 
inappropriate long-term antidepressant use.  
Of the large number of long-term antidepressant users, only a small portion consented 
to participate in this study (less than 15%). Still, we did reach the prospective sample 
size to provide sufficient power for the overtreatment trial, with more practices and 
patients than needed according to the sample size calculations. Patient recruitment is 
a known problem, especially in mental health research (46). According to privacy 
regulations these long-term antidepressant users remain anonymous until giving 
consent, thus reasons for nonparticipation are unknown. It is conceivable that patients 
not willing to participate are more reluctant to change their antidepressant treatment. 
The recruitment success of patients for participation in such an evidence based 
intervention could illustrate the difference between perceived self-interest (by the 
patient) and perceived patient-interest (by researchers and practitioners).  
Due to the pragmatic nature of this study, we did not impose our intervention on the 
patient and their GP. Unfortunately and unexpected, this resulted in noncompliance 
with the given recommendation in almost half of the cases. Further qualitative 
research might be helpful to understand the barriers patients and GPs perceive in 
discontinuing inappropriate, long-term antidepressant use and to be able to construct 
a more effective intervention to reduce inappropriate long-term antidepressant use.  
 
Conclusion 
This study demonstrates the difficulty of correcting inappropriate long-term 
antidepressant use, fuelled by reluctance from both patient and GP to change. A 
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recommendation to discontinue in case of over-treatment is not effective, and maybe 
even counterproductive. It might be useful to forewarn patients about the difficulty to 
discontinue and to encourage using antidepressants for a limited period of time. 
Regular review is necessary to prevent both over and under-treatment.  
 
  
208729-L-bw-Eveleigh
Prescribing Antidepressant Appropriately 
 
55 
References 
 
1.Freeling P. Diagnosis and treatment of depression in general practice. Br J Psychiatry Suppl. 
1993(20):14-9. 
2.Freemantle N, Song F, Sheldon TA, Watson P, Mason JM, Long AF. Managing depression in 
primary care. Qual Health Care. 1993;2(1):58-62. 
3.Paykel ES, Priest RG. Recognition and management of depression in general practice: 
consensus statement. BMJ. 1992;305(6863):1198-202. 
4.Stichting Farmaceutische Kengetallen.  [cited 2013 July]; Available from: http://www.sfk.nl. 
5.Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment of depression. CNS 
drugs. 2006;20(8):623-32. 
6.Piek E, van der Meer K, Hoogendijk WJ, Penninx BW, Nolen WA. Most antidepressant use in 
primary care is justified; results of the Netherlands Study of Depression and Anxiety. PLoS One. 
2011;6(3):e14784. 
7.Raymond CB, Morgan SG, Caetano PA. Antidepressant utilization in British Columbia from 1996 
to 2004: increasing prevalence but not incidence. Psychiatr Serv. 2007;58(1):79-84. 
8.Petty DR, House A, Knapp P, Raynor T, Zermansky A. Prevalence, duration and indications for 
prescribing of antidepressants in primary care. Age Ageing. 2006;35(5):523-6. 
9.Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA. Incidence and 
determinants of long-term use of antidepressants. European journal of clinical pharmacology. 
2004;60(1):57-61.  
10.Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise in 
antidepressant prescribing: a descriptive study using the general practice research database. 
BMJ. 2009;339:b3999.  
11.Spijker J, de Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA. Duration of major depressive 
episodes in the general population: results from The Netherlands Mental Health Survey and 
Incidence Study (NEMESIS). Br J Psychiatry. 2002;181:208-13. 
12.Cruickshank G, MacGillivray S, Bruce D, Mather A, Matthews K, Williams B. Cross-sectional 
survey of patients in receipt of long-term repeat prescriptions for antidepressant drugs in 
primary care. Mental Health in Family Medicine. 2008;5:105-9. 
13.National Institute of Health and Clinical Excellence. Depression: the treatment and 
management of depression in adults (update). 2009; Available from: 
http://guidance.nice.org.uk/CG90. 
14.Multi Disciplinary Guideline Anxiety Disorders. Trimbos; 2009. 
15.Multi Disciplinary Guideline Depression. Trimbos; 2009. 
16.van Weel-Baumgarten EM, van Gelderen MG, Grundmeijer HGLM, Licht-Strunk E, van 
Marwijk HWJ, van Rijswijk HCAM, et al. The NHG guideline Depression (second revision of the 
NHG guideline Depressive disorder). Huisarts Wet. 2012;55(6): 252-9. 
17.Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, et al. Efficacy and tolerability 
of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in 
primary care: a meta-analysis. Ann Fam Med. 2005;3(5):449-56. 
18.Lucassen P, van Rijswijk E, van Weel-Baumgarten E, Dowrick C. Making fewer depression 
diagnoses: beneficial for patients? Ment Health Fam Med. 2008;5(3):161-5. 
19.Fujita A, Azuma H, Kitamura T, Takahashi K, Akechi T, Furukawa TA. Adequacy of continuation 
and maintenance treatments for major depression in Japan. J Psychopharmacol. 2008;22(2):153-
6. 
20.Simon GE. Evidence review: efficacy and effectiveness of antidepressant treatment in primary 
care. Gen Hosp Psychiatry. 2002;24(4):213-24. 
208729-L-bw-Eveleigh
Chapter 3. Too much or too little antidepressant medication: difficult to change. Two RCTs. 
 
56 
21.Muskens E, Eveleigh R, Lucassen P, van Weel C, Spijker J, Verhaak P, et al. Prescribing 
ANtiDepressants Appropriately (PANDA): a cluster randomized controlled trial in primary care. 
BMC Fam Pract. 2013;14:6. 
22.Haro JM, Arbabzadeh-Bouchez S, Brugha TS, de Girolamo G, Guyer ME, Jin R, et al. 
Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with 
standardized clinical assessments in the WHO World Mental Health surveys. Int J Methods 
Psychiatr Res. 2006;15(4):167-80. 
23.Kessler RC, Abelson J, Demler O, Escobar JI, Gibbon M, Guyer ME, et al. Clinical calibration of 
DSM-IV diagnoses in the World Mental Health (WMH) version of the World Health Organization 
(WHO) Composite International Diagnostic Interview (WMHCIDI). Int J Methods Psychiatr Res. 
2004;13(2):122-39. 
24.Kessler RC, Ustün TB. The World Mental Health (WMH) Survey Initiative Version of the World 
Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods 
Psychiatr Res. 2004;13(2):93-121. 
25.Kessler RC, Calabrese JR, Farley PA, Gruber MJ, Jewell MA, Katon W, et al. Composite 
International Diagnostic Interview screening scales for DSM-IV anxiety and mood disorders. 
Psychol Med. 2012:1-13. 
26.Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol 
Med. 1983;13(3):595-605. 
27.Radloff LS. The CES-D Scale: A self-report depression scale for research in the general 
population. Appl Psychol Med. 1977;1:16. 
28.Brook OH, van Hout HP, Stalman WA, de Haan M. Nontricyclic antidepressants: predictors of 
nonadherence. J Clin Psychopharmacol. 2006;26(6):643-7. 
29.Oude Voshaar RC, Gorgels WJ, Mol AJ, van Balkom AJ, Mulder J, van de Lisdonk EH, et al. 
Long-term outcome of two forms of randomised benzodiazepine discontinuation. Br J 
Psychiatry. 2006;188:188-9. 
30.Voshaar RC, Gorgels WJ, Mol AJ, van Balkom AJ, van de Lisdonk EH, Breteler MH, et al. 
Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: 
three-condition, randomised controlled trial. Br J Psychiatry. 2003;182:498-504. 
31.Volkers A, Jong, A. de, Bakker, D. de, Dijk, L. van. Doelmatig voorschrijven van antidepressiva 
in de huisartspraktijk. Utrecht: NIVEL, 2005. 
32.Radloff LS. The CES-D Scale: A self-report depression scale for research in the general 
population. Appl Psychol Med. 1977;1:16. 
33.Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State 
Worry Questionnaire. Behaviour research and therapy. 1990;28(6):487-95. 
34.Bandelow B. Panic and Agoraphobia Scale (PAS).  Assesment scales in depression, mania and 
anxiety. Seattle: Hogrefe & Huber Publishers.; 1999. 
35.Watson D, Friend R. Measurement of social-evaluative anxiety. Journal of consulting and 
clinical psychology. 1969;33(4):448-57. 
36.Voshaar RC, Couvee JE, van Balkom AJ, Mulder PG, Zitman FG. Strategies for discontinuing 
long-term benzodiazepine use: meta-analysis. Br J Psychiatry. 2006;189:213-20. 
37.Gorgels WJ, Oude Voshaar RC, Mol AJ, van de Lisdonk EH, van Balkom AJ, van den Hoogen HJ, 
et al. Discontinuation of long-term benzodiazepine use by sending a letter to users in family 
practice: a prospective controlled intervention study. Drug and alcohol dependence. 
2005;78(1):49-56.  
38.Verbeek-Heida PM, Mathot EF. Better safe than sorry--why patients prefer to stop using 
selective serotonin reuptake inhibitor (SSRI) antidepressants but are afraid to do so: results of a 
qualitative study. Chronic Illn. 2006;2(2):133-42. 
208729-L-bw-Eveleigh
Prescribing Antidepressant Appropriately 
 
57 
39.Leydon GM, Rodgers L, Kendrick T. A qualitative study of patient views on discontinuing long-
term selective serotonin reuptake inhibitors. Fam Pract. 2007;24(6):570-5. 
40.Dickinson R, Knapp P, House AO, Dimri V, Zermansky A, Petty D, et al. Long-term prescribing 
of antidepressants in the older population: a qualitative study. Br J Gen Pract. 
2010;60(573):e144-55. 
41.Kendrick T. Why can't GPs follow guidelines on depression? We must question the basis of 
the guidelines themselves. BMJ. 2000;320(7229):200-1. 
42.Lecrubier Y. Widespread underrecognition and undertreatment of anxiety and mood 
disorders: results from 3 European studies. J Clin Psychiatry. 2007;68 Suppl 2:36-41. 
43.Barkil-Oteo A. Collaborative care for depression in primary care: how psychiatry could 
"troubleshoot" current treatments and practices. Yale J Biol Med. 2013;86(2):139-46. 
44.van Schaik DJ, Klijn AF, van Hout HP, van Marwijk HW, Beekman AT, de Haan M, et al. 
Patients' preferences in the treatment of depressive disorder in primary care. Gen Hosp 
Psychiatry. 2004;26(3):184-9. 
45.Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and 
longer-term outcomes in depressed outpatients requiring one or several treatment steps: a 
STAR*D report. Am J Psychiatry. 2006;163(11):1905-17. 
46.Mason V, Shaw A, Wiles N, Mulligan J, Peters T, Sharp D, et al. GPs' experiences of primary 
care mental health research: a qualitative study of the barriers to recruitment. Fam Pract. 
2007;24(5):518-25. 
208729-L-bw-Eveleigh
 
 
  
208729-L-bw-Eveleigh
 
 
Chapter 4. 
 
Cost-utility analysis of a treatment advice to discontinue inappropriate 
long-term antidepressant use in primary care. 
 
Rhona Eveleigh 
Janneke Grutters 
Esther Muskens 
Richard Oude Voshaar 
Chris van Weel 
Anne Speckens 
Peter Lucassen 
 
Family Practice 2014 Oct;31(5):578-84. 
208729-L-bw-Eveleigh
Prescribing Antidepressants Appropriately 
 
60 
Abstract 
Background: Antidepressant prescriptions have increased exponentially, burdening 
health care costs. 
Objective: To evaluate the costs and effects of an antidepressant cessation advice in 
case of inappropriate long-term use in primary care, i.e. long-term usage without a 
(current) indication. 
Methods: A economic evaluation during 1-year follow-up was performed, from a 
societal perspective, as part of a cluster-randomised controlled clinical trial (PANDA). 
Costs were assessed using the Trimbos/iMTA questionnaire for costs associated with 
psychiatric illness. Health-related quality of life was measured using the EuroQol 5D. 
Outcome was costs per quality adjusted life year (QALY). Missing values were 
estimated using multiple imputation, bootstrap simulations were performed to 
address the uncertainty surrounding the incremental cost-effectiveness ratios (ICERs). 
Results: There was no difference in average QALYs between the intervention (0.70)  
and control group (0.72) [difference −0.02 (95% CI −0.05 to 0.10)]. The intervention 
group, however, was less expensive than the control group (total costs €3636 versus 
€5267, respectively). Most cost-effectiveness pairs were located in the south-west 
quadrant of the cost-effectiveness plane, implying the intervention was less effective 
but also less costly. The ICER of the pooled data was €70 180, meaning that for one 
QALY lost, €70 180 is saved. 
Conclusions: This study shows that an antidepressant cessation advice given to 
patients (and their FPs) with inappropriate long-term antidepressant usage, albeit not 
effective, does seem to result in a reduction of societal costs. This reduction in costs is 
mostly due to reduction of productivity losses, possibly due to patient empowerment 
and loss of stigma. 
Key words: Antidepressant medication, anxiety/anxiety disorder, depression/mood 
disorder, primary care, health economics. 
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Introduction 
 
Depression and anxiety disorders are highly prevalent, with the prevalence still rising. 
Antidepressant drugs have been proven to be moderately effective for these disorders 
(1,2). The use of these drugs has increased exponentially over the past years. In the 
past 15 years the use of antidepressants has increased with more than 230% in the 
Netherlands, burdening health care costs (3). The total cost of these drugs (262 daily 
doses distributed in the Netherlands in 2011) remains substantial, even though most 
antidepressant have lost their patent, thus being much less expensive than they used 
to be. Current guidelines advise to be more restrictive with antidepressant use, to 
prevent overtreatment with these drugs resulting in improved quality of life (4).  
  
Studies suggest that a large proportion of antidepressant treatment is inappropriate 
(5), consequently the question rises whether the use of antidepressant drugs can be 
reduced in order to lower the burden on medical costs. Moreover, polypharmacy with 
psychotropic drugs leads to high mental health care and community costs (increase of 
~20%) (6). It has been shown that providing feedback to prescribers on their 
prescription behaviour for individual patients can prevent polypharmacy (7). 
 
Objective 
In a recent randomised controlled clinical trial the effect of an antidepressant 
cessation advice, in patients with long-term antidepressant use without a (current) 
indication for continuation was compared with usual care in primary care. The aim of 
the current study is to evaluate the cost-effectiveness of this intervention. 
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Methods 
 
Study design and participants of RCT  
We collected data for this cost-effectiveness analysis alongside a cluster randomised 
controlled trial on the effectiveness of a cessation treatment for inappropriate long-
term antidepressant use in primary care (PANDA study). The study design of the 
PANDA study of the cluster randomised controlled trial has been published elsewhere 
(8). We recruited 146 participants from 46 family practices. For inclusion participants 
had to be a long-term antidepressant user (i.e. more than 9 months consecutively). 
Exclusion criteria were: (i) appropriate use of long-term antidepressants according to 
the multidisciplinary guidelines for depressive and anxiety disorders (i.e. a history of 
recurrent depression (≥3 episodes) and/ or a recurrent psychiatric disorder with at 
least two relapses after antidepressant discontinuation); (ii) Presence of a current 
psychiatric diagnosis for which antidepressants may be effective (i.e. depressive 
disorder, dysthymia, generalised anxiety disorder, panic disorder or social phobia); (iii) 
Non-psychiatric indication for long-term antidepressant usage, for example 
neuropathic pain; (iv) Current treatment in a psychiatric setting; (v) Current diagnosis 
of substance use disorder; (vi) History of psychosis, bipolar disorder or obsessive 
compulsive disorder; (vii) Inability to perform the necessary assessment due to a 
hearing impairment and/or insufficient understanding of the Dutch language. 
 
Intervention 
Twenty-three family practices were randomised to the intervention group. The 
intervention implied the discontinuation of inappropriately used antidepressants, 
according to the Dutch multidisciplinary guidelines for depressive and anxiety 
disorders. This advice was drafted by an experienced Family Physician (FP) and 
psychiatrist independently. The FPs received a letter stating that the patient did not 
meet the criteria for a depressive or anxiety disorder in the past year. In the control 
group (23 FPs), we asked the FPs to continue their usual care. 
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Cost measures 
In this economic evaluation we used the societal perspective. Resource use was 
collected using the Trimbos/iMTA questionnaire for Costs associated with Psychiatric 
illness (TiC-P) (9). The Tic-P consists of information on the use of health services and 
resources as well as productivity losses due to illness over the past 3 months. 
Participants were asked to complete the TiC-P at baseline and after 3, 6, 9 and 12 
months follow-up. We used standardised Dutch unit prices; when not available, prices 
were based on tariffs (9). Cost of medication was based on the Dutch 
‘pharmacotherapeutic compass’ (10). The cost of productivity loss was calculated 
according to the friction cost method: the number of hours patients were absent from 
their job multiplied by the actual gross wage per hour. The cause of absence was not 
taken into account. In the friction cost method, the friction period was defined as the 
time needed to restore the initial production level. Thus productivity cost was only 
counted for as long as it costs to replace someone, after this period the costs fall back 
to zero (11). For the friction cost, the tariff and friction period of 154 days were  
obtained from the TiC-P manual (9). The cost of the intervention was accounted for by 
adding up the expenses for the interviewers, the FP and psychiatrist (for the 
assessment of eligibility and treatment advice) and administrative task. Extra practice 
visits to the FP (e.g. to discuss the given treatment advice) are already accounted for in 
the TiC-P. Price indices were used to convert all costs to the 2012 price level. 
 
Outcome measures 
Effectiveness was expressed as quality adjusted life years (QALY). A QALY is a measure 
of life expectancy, weighted by the health related quality of life represented by utility 
scores. Participants completed the EuroQol (EQ-5D) health status questionnaire at 
baseline and 3, 6, 9 and 12 months to obtain information on quality of life (12). The 
EQ-5D has been proven suitable for calculating QALYs in economic evaluation of health 
care interventions for patients with mental disorders (13). EQ-5D responses were 
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converted to utility weights per time period using a published algorithm derived from 
the Dutch population (14). The QALY was calculated for each patient by multiplying 
duration by the time-weighted average of his or her utility values per time period. 
 
Data analysis 
Costs per 3 months (3, 6, 9 and 12 months) were added up, plus the cost of the 
intervention, to reach the total costs of direct and indirect health care costs during the 
year of follow-up. Missing data were handled using multiple imputation. Instead of 
filling in a single value for each missing value, Rubin’s multiple imputation procedure 
generates ‘m’ data sets, each of which replaces each missing value with a plausible 
value, that represent the uncertainty about the right value to impute (15). With 
regression models the missing value of a specific variable is predicted using other 
variables, in this case baseline patient characteristics and known utilities and costs. In 
the multiple imputation method the imputed variables are drawn from the density 
function as generated by the regression model. This results in statistically valid 
inferences that properly reflect the uncertainty due to missing values (16). We created 
five data sets (m = 5). As cost data are generally highly skewed and not distributed 
normally, bootstrap simulation with 1000 replications was performed. For the same 
reasons, QALY scores were also bootstrapped with 1000 replications, thus facilitating 
estimation of 95% confidence intervals of the mean cost and mean QALY. The 95% 
confidence interval of the costs and effects was estimated using the percentile 
method. The incremental cost-effectiveness ratios (ICER) were calculated and 
bootstrapped and presented in cost-effectiveness planes. The data from the 5 MI data 
sets were then combined together to produce estimates and confidence intervals that 
incorporate the missing uncertainty. Main analyses and multiple imputation were 
performed in SPSS Statistics, version 20. Bootstrap simulation was performed using 
case re-sampling in a customised macro using Microsoft Excel and Visual Basic. 
 
 
208729-L-bw-Eveleigh
Prescribing Antidepressants Appropriately 
 
65 
Secondary analyses 
To assess the robustness of the results, we compared the results with the analysis of 
the complete cases. In addition, we performed an analysis with a health care 
perspective, meaning that only direct health care costs were taken into account. In this 
analysis, we excluded the productivity losses from the analysis. 
 
 
Results  
 
Summary of main results of RCT 
The PANDA study showed the difficulty of discontinuing long-term antidepressant use. 
A very small number of participants was able to successfully discontinue their 
antidepressant. No difference was found in the proportion of patients successfully 
discontinuing long-term antidepressant use between the control and intervention 
group (8%, 95% CI 4–16% versus 6%, 95% CI 2–14%). A significantly higher relapse rate 
was found in the intervention group (n = 18; 36%, 95% CI 25–50%) in comparison to 
control (n = 10; 14%, (95% CI 8–25%) (P = 0.015). Surprisingly, this difference was not 
associated with antidepressant discontinuation or symptom severity. 
 
Participants/baseline characteristics 
In the randomised controlled trial, we included 146 patients with long-term 
antidepressant use (Fig. 1). Baseline characteristics of the participants are summarised 
in Table 1. At baseline, we found no significant differences in utility scores, direct 
health care costs and productivity losses (indirect health care costs) between the 
intervention and control group. We obtained complete data for the cost-effectiveness 
analysis for only 75 patients, due a high dropout rate in returning all 3-monthly 
questionnaires. Fortunately, most participants did return two or more questionnaires 
(Figure 1). We found no differences between the patients completing all 
questionnaires compared to those who did not. 
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Figure 1. CONSORT flowchart of patient inclusion and analysis. 
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Table 1. Inappropriate long-term (>9 months) users of antidepressants in the Netherlands at 
start of the PANDA study. 
 
 
Base case analysis, cost-utility analysis 
The intervention did not have any effect on the quality of life in this study. Over one 
year, patients in the intervention group yielded on average 0.70 QALYs, while patients 
in the control group yielded 0.72 QALYs. So, the discontinuation advice resulted in a 
loss of −0.02 (95% CI −0.05 to 0.10) QALYs (Table 2). However, the intervention group 
was also found to be less expensive than the control group (total costs €3636 versus  
€5267, respectively). The cost of the intervention amounted to €22.30 per patient. 
When comparing the intervention and control groups, the largest difference in cost 
was found in the indirect costs, although this did not reach statistical significance 
(Table 2). The ICER of the pooled data was €70 180, meaning that for one QALY lost, 
€70 180 is saved. The pooled bootstrapped results are shown in Figure 2 as a cost-
effectiveness plane. Most cost-effectiveness pairs are located in the south-west 
quadrant, implying that the intervention studied is less effective but also less costly.  
 Control group (n=76) Intervention group (n=70) 
Mean age in years (SD) 56 (14.3) 56 (12.9) 
Male 24 (31.6%) 20 (29%) 
   
Marital status   
Married or living together 60 (79%) 56 (81%) 
Single 9 (12%) 9 (13%) 
Widow/widower 7 (9%) 2 (3%) 
Separated or divorced 0 2 (3%) 
   
Employment status   
Labour 30 (44%) 29 (45%) 
Housewife/man 11 (16%) 10 (16%) 
Elderly pension 19 (28%) 18 (28%) 
Student 1 (2%) 0 
Unemployed due to health 
problems 
3 (4%) 6 (9%) 
Unemployed due to other 
reasons 
4 (6%) 1 (2%) 
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Table 2. Pooled effectiveness (QALY) and costs (in euro) in the control (n=76) and the 
intervention (n=70), shown as the mean (standard error of the mean). 
 
 
 
Figure 2. Pooled, bootstrapped costs and effects for cost per QALY, showing five times 1000 
bootstrap replications for incremental cost-effectiveness of the intervention compared to the 
control from a societal perspective. Costs are on the y-axis in euro, and effects on the x-axis. 
 
 
 
The CEAC (Fig. 3) indicates that the probability of the intervention being cost-effective 
decreases with a increasing threshold value. In other words, the smaller the savings 
society demands per QALY lost, the more probable it becomes that the intervention is 
cost-effective. In this case the CEAC shows that if society demands to save €80.000 per 
QALY lost, the probability of the intervention being cost-effective is 47%. But if society 
 Control Intervention Difference (95%CI) 
QALY 0.72 (0.03) 0.70 (0.03) -0.02 (-0.05; 0.10) 
    
Costs    
Health care costs € 2091 (570) €  2034 (313) -57 (-1244; 1359) 
Productivity losses € 3175 (1198) € 1579 (439) -1596 (-906; -4098) 
Total costs € 5267 (1725) € 3636 (667) -1631 (-2039; 5301) 
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demands to save only €20.000 per QALY lost, the probability of cost-effectiveness rises 
to 71%. 
 
Secondary analyses 
The complete case analysis showed slightly different results. While, the intervention 
was less effective (−0.03 QALYs), it was also more expensive (€1088). The CEAC (Fig. 3) 
indicates that the intervention is not likely to be cost-effective. When deducting the 
productivity losses, thus using the health care perspective, savings per QALY lost did 
not differ significantly from the analysis from the societal perspective. The intervention 
group was again found to be less expensive than the control group (total costs €1778 
versus €1875, respectively). The CEAC shows a decreased probability of cost-
effectiveness (Fig. 3). 
 
 
Figure 3. Cost-effectiveness acceptability curves for cost benefit per QALY lost. The curves 
indicate the probability (y-axis) of the intervention being cost-effective compared to control, 
given the threshold value (x-axis) for a QALY. 
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Discussion 
 
In the effort to reduce the costs of long-term antidepressant use, a discontinuation 
advice does not appear to be effective, but does reduce costs from a societal 
perspective. The ineffectiveness of the intervention will be described more extensively 
elsewhere (Eveleigh et al., submitted for publication recently). 
 
The difference found in the utility score was a merely −0.02. The minimally important 
difference for the EQ5D is considered 0.07 points (17). Thus, as well as not being 
statistically significant, the difference found also does not seem to be clinically 
relevant. As in both groups only a small number of patients actually discontinued their 
antidepressant usage, an improvement in quality of life was not expected.  
 
In the intervention group we found a slight reduction in costs, due to reduced 
productivity losses in the intervention group (societal perspective). This was not a 
result of the actual discontinuation of the antidepressant, as this did not differ 
between the intervention and control group. The reduction of productivity losses could 
be explained by a loss of stigma that accompanied the advice to discontinue the long-
term antidepressant use. Not having a psychiatric diagnosis (anymore), can empower 
patients, leading to a reduction of productivity losses. By prescribing antidepressants 
and by continuing these prescriptions long-term, patients apparently label themselves 
as ‘being ill’ and thus act upon this label. A periodical review by the FP is necessary to 
possibly declare the patient healthy and remove this label.  
 
This result also illustrates the paradox of primary care (18). The effectiveness of an 
intervention in primary care should not only be assessed by disease-specific outcome 
measures, but also by taking a broader perspective into account. A societal perspective 
takes not only disease-specific costs into account, but also the patient as a whole in a 
community based context.  
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The ICER of the pooled data was €70 180, meaning that for one QALY lost, €70 180 is 
saved. To date, there is no consensus about a reasonable threshold value for cost- 
effectiveness. In the Netherlands thresholds used for the appraisal of new 
interventions are around €80.000 per QALY gained (19). The selling price of a QALY 
(willingness to accept to lose a QALY) seems to be larger than the buying price of a  
QALY (willingness to pay to gain a QALY) (20). The questions rises how much money 
does society want to save, to be willing to lose a QALY, thus for an intervention to be 
‘decrementally’ cost-effective. In this study we found that the higher the selling price, 
the lower the probability of the cost-effectiveness of the intervention. With a 
threshold of €80.000 per QALY lost, the probability of the intervention being cost-
effective is 47%. 
 
Strengths and limitations 
To our knowledge, this is the first cost-effectiveness analysis of a cessation advice for 
inappropriate long-term antidepressant use. Our aim was to reduce inappropriate 
antidepressant use, consequently reducing societal costs and simultaneously 
sustaining (or even improving) quality of life. We were able to recruit a large number 
of family practices, thus resulting in a good representative of the Dutch family 
practices. 
 
This study was undertaken alongside an RCT (PANDA study) to evaluate the cost-
effectiveness. Major drawback was the number of missing values, due to drop out in 
completing the 3-monthly questionnaires. However, drop out numbers were equally 
distributed between the intervention and control group. Fortunately, most participants 
did return two or more questionnaires. The use of MI to estimate the values of missing 
costs and utilities has been encouraged in the literature, to strengthen the robustness 
of cost-effectiveness analyses alongside randomised controlled trials (16). The  
complete case analysis showed a slightly higher burden on cost with the intervention, 
in contrast with the analysis performed using multiple imputations to estimate the 
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missing values. Despite this, the results of the complete case analysis did match the 
95% confidence interval of the pooled data of the multiple imputations. 
 
Another limitation is the time horizon of 1 year to evaluate the cost-effectiveness of 
this intervention. In the past years most modern antidepressants have lost their 
patent, leading to cheaper medications. For example, the most frequent prescribed 
antidepressant ‘paroxetin’ when using a 20 mg tablet once a day, will cost ~11 euro 
per year. For discontinuation of this drug to be cost-effective from a health care 
perspective, a very small cost of the intervention will be needed or a large positive 
effect on the quality of life. This again, illustrates the importance of taking a broader, 
societal perspective in primary care research. 
 
Finally, because the friction cost method was used to calculate productivity losses, the 
maximum productivity loss per patient was 154 days. Alternatively, the human capital 
approach can be used to estimate productivity losses. This approach estimates the 
value of all potentially lost productivity, whereas the friction cost method attempts to 
quantify actual productivity losses. The friction cost method is therefore considered to 
be more realistic, and recommended in the Dutch guideline for costing research (21). It 
generally leads to lower productivity costs than the human capital method (22). 
 
Conclusions 
This study shows that a antidepressant cessation advice given to patients (and their 
FPs) with long-term antidepressant usage without a (current) indication, albeit not 
effective, does seem to result in a reduction of societal costs. This reduction in costs is 
mostly due to reduction of productivity losses, possibly due to patient empowerment 
and loss of stigma. 
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Abstract 
Background: long-term antidepressant use has increased exponentially, though this is 
not always appropriate. The PANDA-study showed that patients using antidepressants 
long-term without a proper indication were apprehensive to stop: only half were 
willing to attempt to discontinue their antidepressant use. 
Objectives: to explore the barriers and facilitators patients using antidepressants long-
term without a proper indication, perceive towards the discontinuation of these drugs. 
Methods: semi-structured interviews with participants from the PANDA study, a 
cluster-randomized controlled trial on inappropriate long-term antidepressant use in 
General Practice. Participants were purposively sampled to ensure diversity in age, sex 
and the intention to discontinue the antidepressant. Analysis was performed as a 
iterative process, based on the constant comparative method. Data collection 
proceeded until saturation was reached. 
Results: 16 participants were interviewed. The most apparent barrier was the notion 
that antidepressants are necessary to supply a deficiency of serotonin. Fear (of 
recurrence, relapse or to disturb the equilibrium) was also prominent and prior 
attempts fuelled these anticipations. Facilitators were information on duration of 
usage given at the time of first prescription and confidence in a successful attempt. 
Next to the barriers and facilitators, we found ambivalence towards the antidepressant 
use.  
Conclusion: The serotonin deficiency as explanation for antidepressant effectiveness 
promotes life-long use and hinders discontinuation of antidepressant treatment. The 
prospect of discontinuation at first prescription can facilitate a future discontinuation 
attempt. GPs should be aware of the patients’ fears and attributions towards 
antidepressant use/discontinuation.  
Key words: antidepressant agents, primary health care, depressive disorder, anxiety 
disorder, general practice, inappropriate prescribing. 
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Introduction 
 
Antidepressants are an evidence-based treatment for depressive and anxiety disorders 
(1-3). However,  with the prescriptions of antidepressant drugs rising exponentially (4), 
the appropriateness of these prescriptions has been questioned (5-7).  
 
A number of factors have been suggested to contribute to the increasing numbers of 
antidepressant prescriptions, including increased prevalence, improved recognition 
and management. Long-term usage has been found to contribute largely to the 
growing amount of antidepressant use (5, 8, 9). Guidelines differ in detail on 
appropriateness of long-term antidepressant prescriptions, but in general recommend 
to continue medication after adequate first response. The duration of this continuation 
is set between 6 and 12 months, depending on the guideline (1, 10, 11). Maintenance 
therapy is recommended for patients with recurrent depression, with recurrent being 
defined as either 2 (1, 10) or 3 episodes (11). Maintenance therapy could also be 
suggested for patients with other risk factors for relapse.  
 
We sought to minimize inappropriate long-term (≥9 months) antidepressant usage 
with the Prescribing ANtiDepressants Appropriately (PANDA) study (12, 13). This study 
demonstrated the difficulty in discontinuing long-term inappropriate antidepressant 
use. Patients were reluctant to accept a discontinuation advice although continued use 
of the antidepressant was deemed inappropriate according to clinical guidelines (11, 
14). In almost half of the cases the discontinuation advice was rejected by the patient.  
 
Patients’ experiences of antidepressants use were summarized in a large meta-
ethnography (15). In summary, patients constantly evaluate their antidepressant use 
by balancing risks and benefits, hopes and fears, positive and negative self-images. A 
tension was found between ‘feeling well’ and ‘being well’, further described as the 
difference between self-determination and psychological dependency. When focussing 
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on long-term antidepressant users, antidepressants were seen as a threat to 
autonomy.  Antidepressants doubled the stigma, with the antidepressant as the 
evidence for failure to cope with everyday problems. On the other hand, 
antidepressant use also reduced stigma, with depression being seen as a physical 
illness and the ‘serotonin deficiency’ being treated with antidepressants. The fear of 
relapse and withdrawal symptoms is considered more frightening than the prospect of 
continuing unnecessary medication, leading to continued use:  “better safe than 
sorry”(16). Some patients believe their condition to be chronic and requiring life-long 
treatment, while at the same time feeling uncomfortable with this prospect (16-18).  
Research on the non-adherence to antidepressants (after initial acute phase 
treatment) has found similar beliefs: harmfulness beliefs and necessity beliefs are 
weighed and this trade-off results in adherence (19-21). It is unknown whether 
patients using long-term antidepressants without a current indication for the 
continued usage have the same attitudes towards their use. 
 
With this study, we aim to explore the attitudes of these specific patients, using long-
term antidepressants without a proper current indication, towards the discontinuation 
of these drugs and to explore their attitudes towards the discontinuation advice they 
had received when participating in the PANDA-study. We were looking for experiences 
and cognitions of patients towards which counselling to discontinue inappropriate 
antidepressant use could be directed. 
 
 
Methods 
 
Design 
We performed a qualitative study, using in-depth semi-structured interviews. 
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Participants 
Patients were selected from the participants of the PANDA-study, a cluster-
randomized controlled clinical trial on long-term antidepressant usage (13). In the 
PANDA-study patients were included who used antidepressants for 9 months or 
longer, i.e. long-term antidepressant users. These patients underwent a psychiatric 
diagnostic evaluation to determine the appropriateness of their antidepressant use, 
according to the clinical multidisciplinary guidelines in the Netherlands (11, 14). 
Patients were excluded in case of: 1) current treatment in a psychiatric in- or 
outpatient clinic; 2) appropriate use of long-term antidepressants according to the 
Dutch guidelines for depressive and anxiety disorders (i.e. a history of recurrent 
depression (≥3 episodes) and/or a recurrent psychiatric disorder with at least two 
relapses after antidepressant discontinuation); 3) history of psychosis, bipolar disorder, 
or obsessive compulsive disorder; 4) current diagnosis of substance use disorder 
(excluding tobacco); 5) non-psychiatric indication for long-term antidepressant usage, 
e.g. neuropathic pain; 6) hearing impairment and/or insufficient understanding of the 
Dutch language. 
 
Patients who had been assigned to the intervention group in the overtreatment trial of 
the PANDA-study were selected for this qualitative study (13). Thus including only 
those patients using antidepressants long-term (≥ 9 months) without a current 
indication for continued usage. These patients had received the recommendation, via 
their own GP, to discontinue their antidepressant use. Patients who did not consent to 
be contacted for further research after the PANDA-study were excluded (24%, 
n=17/70). Patients were purposively sampled to ensure diversity in age, sex, the 
intention to comply with the advice and actual discontinuation of the antidepressant 
during the course of the PANDA study. Data collection proceeded until saturation was 
reached.  
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Data gathering and analysis 
Individual semi-structured interviews were conducted in January and February 2014 
(see supplement for topic guide). The interviews were undertaken by telephone, as 
was the preference of all participants, by RE and lasted an average of 15-20 minutes. 
RE is a physician and trained interviewer. All interviews were recorded and transcribed 
verbatim. Thematic analysis was carried out using a qualitative software package 
(Atlas.ti, version 7.1.5, Cincom systems). Analysis began once data collection 
commenced as an iterative process, based on the ‘constant comparative method’(22). 
Coding was carried out independently by two of the authors (RE and PL), followed by a 
series of discussions to derive a coding framework. When no consensus could be 
reached, a third author (AS) was consulted. Exemplary quotations were selected to 
demonstrate the findings, followed by a short description of the cited participant: 
gender, age, acceptance or rejection of the discontinuation advice given in the PANDA 
study and actual discontinuation of the antidepressant use. 
This study was exempted from evaluation by the institutional ethics committee 
Nijmegen, as it was considered an addition to the approved PANDA-study (institutional 
ethics committee Nijmegen registration number NL29718.091.09). 
 
 
Results 
 
In total 16 patients were interviewed. Eleven were female (69%), mean age was 57 
years, with a range of 33-81. Seven patients intended to comply with the 
discontinuation advice during the PANDA-study, three patients actually discontinued 
their antidepressant (during or after the PANDA-study). 
Several themes emerged, which we have grouped into barriers, facilitators and 
ambivalence towards discontinuing long-term antidepressants (table 1). 
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Table 1. Emerging themes concerning the discontinuation of long-term antidepressant use. 
Barriers Facilitators Ambivalence 
Attributions  
- Serotonin deficiency  
- Chronic condition 
- Antidepressants do 
no harm 
Information 
- Known limited duration 
of use at first 
prescription 
- Recommendation to 
discontinue; 
professionals opinion 
use is no longer 
indicated 
Trade-off between 
barriers and facilitators 
Fear 
- Recurrence or 
relapse 
- Disturb the balance 
- Effect on 
relationships 
Fear  
- Addiction 
- Stigma 
- Shame 
- Long-term adverse 
effects 
Lack of motivation, 
despite no barriers 
Prior attempts Self-confidence in success   
 Trust in GP (safety net and 
counsellor) 
 
 Practical motives (e.g. drivers 
license) 
 
 
 
Barriers 
Attributions 
Patients described their antidepressant use as supplying an, otherwise deficient, 
substance. This substance was perceived as ‘needed’ to function normally as this 
deficiency caused the depression, resulting in the acceptance of lifelong dependency.  
 
“I just need it, yeah. For me, this isn’t a psychological illness, it’s physical. 
And my body isn’t able to make enough serotonin, so I take the pill to supply it.”  (ID 
129: female ,66 yr, rejected advice and did not discontinue) 
 
The comparison with diabetes and insulin was also made.  
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“She [the GP] told me, you should see it like you have a deficiency in your 
brain, you miss a certain substance and the medicine supplies it. She told me, it’s just 
like someone with diabetes who needs insulin for the rest of their life. Well, I kind of 
believe that, so never questioned my use since.” (ID 302: female, 74yr, rejected advice 
and did not discontinue) 
 
Another attribution that played a role was the belief to be suffering from a chronic 
condition, and thus in need for lifelong medication. Antidepressants were also 
described as being a natural and bodily substance, thus ‘it surely could do no harm’. 
 
Fear 
Fear of recurrence or relapse was a great barrier to attempt to discontinue. Patients 
were afraid of reliving the negative feelings they had in the past and anticipated this 
recurrence if they would discontinue.  
 
“That’s my biggest fear. The misery I was in, before I got these medicines, I 
never want to relive that. I never want to go back to how I felt then. And because of this 
fear, I just can’t attempt to stop them.”(ID 129: female, 66 yr, rejected advice and did 
not discontinue) 
 
“…if I would remain to feel well, I would quit tomorrow, but... to go through 
the hell I went through again? No.” (ID 170: female, 64yr, rejected advice and did not 
discontinue) 
 
Others described the fear of disturbing the balance or equilibrium they had achieved. 
 
“I have found a balance, emotionally that is. Well, and I don’t want to disturb 
this balance.” (ID 262 male, 63yr, rejected advice and did not discontinue)  
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“Well, I am feeling very well, I am very stable. I’m in harmony, I don’t have 
any mood swings or anything. I don’t think I could feel any better than I do now. Also 
mentally. So, I won’t risk it. I won’t attempt it, maybe it would be successful, but I won’t 
dare to try.” (ID 302: female, 74yr, rejected advice and did not discontinue) 
 
Another fear was the effect an antidepressant discontinuation would have on their 
relationship with their partner.  
 
“I don’t really want to take the risk. If I stop with the antidepressive 
medication, that A the symptoms would come back, but also B there would be more 
tension in my relationship and I would keep getting into a fight.” (ID 262: male, 63jr, 
rejected advice and did not discontinue) 
 
“She [my wife] really does understand that I would like to try to taper, it’s not 
like she doesn’t want me to. But she said please take the pills, because you’re so much 
easier to handle... haha.. So I just keep taking them.” (ID 219: male, 59yr, rejected 
advice and did not discontinue) 
 
Prior attempts 
Fears and attributions were sometimes fuelled by experiences during prior 
discontinuation attempts. Because of difficulty in tapering and discontinuation 
symptoms, attributions concerning life- long need and anticipation fear were 
reconfirmed. Attempts to discontinue were frequently without informing or receiving 
guidance from their GP. 
 
“Yeah well, then [prior attempt] my tolerance level lowered and became 
agitated. I also had more feelings of loneliness and abandonment, so I didn’t feel well at 
all and didn’t know what to do. Yeah, that kept on coming back. I started to think, what 
good is this? Why I am doing this? Why should I stop? Then I restarted the 
medication.” (ID 262: male, 63jr, rejected advice and did not discontinue) 
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Facilitators 
Mentioning the limited duration of antidepressant usage at first prescription was 
found to be facilitating in the tapering process.  
 
“So, from the start I knew that we would stop (the antidepressant) as soon as it 
was possible.” (ID 186: male, 68yr, accepted advice but did not successfully 
discontinue)  
 
“My GP made it very clear, it (the antidepressant) is only a temporary 
solution, it will help, but the problem lies elsewhere.” (ID 228: female, 47yr, accepted 
advice but did not successfully discontinue) 
 
The antidepressant discontinuation advice was seen by some as the nudge needed to 
start tapering their antidepressant. 
 
“…if you get the advice, that it should be possible, then you start to think, may 
I should try. Because you do want to live without. It gave me the extra nudge that I 
needed to give it a try. I already questioned my use frequently, like, you think that this 
tablet works well, but you’re not sure, are you? I’m glad I participated in this study, 
that I got the validation I needed, that I could do without.” (ID 165: female, 45yr, 
accepted advice and successfully discontinued) 
 
  “Without the advice I would just have kept taking the medication.” (ID 186: 
male, 68yr, accepted advice but did not successfully discontinue) 
 
The confidence a patient had beforehand in the success of a discontinuation attempt, 
was of importance. If the patient could be convinced the attempt would be successful, 
the fear to discontinue would diminish. The GP played  an important role in this, both 
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as a ‘safety net’ and as a ‘partner or counsellor during the attempt’. Patients need to 
have trust in their GP to be able to commence a discontinuation attempt. 
 
“...and that my GP is willing to say, no we won’t wait and see, but will take my 
symptoms seriously. Then I thought, now I can try (to taper), if I have a kind of safety 
net. I had more confidence in myself, so I gave it a go. It was scary.” (ID 239: female, 
34yr, rejected advice and did not discontinue) 
 
As a motivator to discontinue their antidepressant use, patients mentioned fear of 
addiction.  In addition, they felt it could not be healthy to use antidepressants forever 
and were worried about long-term adverse effects. Other motivating factors to 
discontinue were the amount of stigma and shame the patient felt by having to rely on 
antidepressants. The ability to be able to function on their own without being 
dependent of antidepressants was also a contributor. 
 
“I really wanted to be able to do it on my own. To live my life and not stay 
standing because of medication.” (ID 239: female, 34 yr, rejected the advice and did not 
discontinue) 
 
One patient mentioned a practical issue, why she wanted to discontinue. She 
experienced the hassle of the medical examination to extend her driver’s licence, after 
declaring to use antidepressant medication. 
 
Ambivalence 
We found a great ambivalence in the use of antidepressants. Some patients described 
the struggle between barriers and motivators to discontinue, but others did not nor 
did they recognize this struggle when prompted. These patients had no motivation to 
discontinue, despite the lack of any barriers.  
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 “Well, you can just keep the medicine as maintenance therapy. But I haven’t 
had any symptoms for a long while, so there isn’t really any reason not to try to stop 
using it, is there? Sometimes I even skip one, just because I don’t feel like taking it. But 
I do always call for a repeat prescription. I just haven’t done it, stop completely.” (ID 
161: female, 45yr, accepted advice but did not successfully discontinue)  
 
 
Discussion 
 
We found barriers and facilitators to discontinue long-term antidepressant use without 
a proper indication. The most apparent barrier was the notion that antidepressants are 
necessary to supply the deficient serotonin. This serotonin deficiency resulted in 
patients expecting continued use of their medication. Presumably this is the result of 
the explanation GPs give to their patients at first prescription, or at least what patients 
(choose to) remember. The biological model (23) for depression seems to backfire, 
making it difficult to persuade the patient to discontinue the drug. This is an important 
and new finding. GPs must keep this in mind while explaining the course of treatment 
for depressive and anxiety disorders.  
 
Fear (of recurrence, relapse or to disturb the equilibrium) was also prominent and 
prior attempts fuelled these anticipations. These fears have previously been described 
in the literature for all antidepressant users (16-18) and our study confirmed that long-
term antidepressant users, who according to the guidelines should discontinue their 
use, face the same fears.  As facilitators for an attempt, patients mentioned a known 
limited duration of usage at the time of starting the drug and the confidence in a 
successful attempt which could be enforced by guidance and reassurance by the GP. 
Also, patients felt that being able to live without their antidepressants empowered 
them.   
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In addition, we also found ambivalence towards antidepressant use. With the lack of 
motivation to discontinue, most patients just kept on using them, even when no 
barriers were apparent.  Malpass et. al. (15) describe that patient find a balance 
between pro’s and con’s. In this study, we also found this trade-off. Patients described 
motivators and facilitators to discontinue, but these were overruled by the barriers 
they perceived and thus did not actually discontinue. Our results also show that for not 
all patients this is a conscious choice. The willingness to discontinue seems to be 
important. Some patients only needed a little ‘nudge’, others plainly refused to 
discontinue their antidepressant. The importance of willingness to discontinue has also 
been indicated in long-term benzodiazepine use (24). Where benzodiazepines are seen 
as addictive, antidepressants are not. However, some patients do seem psychologically 
dependant.   
 
Study strengths and limitations 
This paper contributes to a relatively small amount of literature on long-term 
antidepressant usage.  As being a part of the PANDA study, the sample of patients was 
limited to the participants of this study: patients using antidepressants long-term, 
without a current clinical indication for this usage and who had received a 
recommendation to discontinue their use. By purposive sampling we were able to 
provide a good mix of patients reluctant and patients willing to discontinue long-term 
antidepressants, in addition to gender and age. This resulted in a study of patients who 
are usually hard to reach in mental health research, but are very relevant to general 
practice.  
Long-term antidepressant users are a selection of patients prescribed antidepressants, 
who have already went through the process of acceptance and adherence to this 
medication. We can imagine these patients have found a balance between pro’s and 
con’s, thus resulting in their long-term usage. Therefore the findings in this study 
cannot be extrapolated to all antidepressant users. In addition, as with all qualitative 
research, our findings may not be exhaustive. 
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Recommendations for clinical practice 
At first prescription, GPs should realize that by explaining the effects of 
antidepressants as a supplement for a deficiency in serotonin, patients could perceive 
antidepressants as a lifelong necessity.  
 Discussing an anticipated duration of antidepressant usage at first prescription, could 
facilitate a discontinuation attempt in the future. 
Before recommending the discontinuation of long-term inappropriate antidepressant 
use, an exploration of existing fears and expectations is constructive. Previous 
attempts to taper could have taken place without the knowledge of the GP, and 
without any guidance or counselling. Cognitive therapy could possibly be used as a 
supportive therapy in the tapering process when fear is apparent.  
 
Conclusion 
Discontinuing inappropriate long-term antidepressant usage is difficult. The serotonin 
deficiency as explanation for antidepressant effectiveness promotes life-long use and 
hinders discontinuation of antidepressant treatment. The prospect of discontinuation 
at first prescription can facilitate a future discontinuation attempt. GPs should be 
aware of the patients’ fears and attributions towards antidepressant 
use/discontinuation when discussing antidepressant discontinuation.  
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Abstract 
Objectives: The doctor-patient relationship has been linked to patient satisfaction, 
treatment adherence, and treatment outcome. Many different instruments have been 
developed to assess this relationship. The large variety makes it difficult to compare 
results of different studies and choose an instrument for future research. This review 
aims to provide an overview of the existing instruments assessing the doctor-patient 
relationship. 
Study Design and Setting: We performed a systematic search in PubMed, PsychInfo, 
EMBASE, and Web of Science for questionnaires measuring the doctor-patient 
relationship. We appraised each instrument ascertaining the questionnaires focused 
on the doctor-patient relationship. We compared the content and psychometric 
characteristics of the instruments. 
Results: We found 19 instruments assessing the doctor-patient relationship. The 
instruments assess a variety of dimensions and use diverse conceptual models for the 
doctor-patient relationship. The instruments found also vary in terms to which they 
have been psychometrically tested. 
Conclusion: We have provided an overview of 19 instruments assessing the doctor-
patient relationship. The selection of an instrument for future research should be 
based on the model or conceptual basis of the doctor-patient relationship that is most 
applicable to the study objectives and the health care field in which it will be applied. 
Keywords: Doctor-patient relationship; Therapeutic alliance; Trust; Questionnaire; 
Instruments; Review. 
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 Introduction 
 
The relationship between doctors and patients is an important factor in the 
effectiveness of treatment. In 1927, Peabody (1) proposed that ‘‘the practice of 
medicine in its broadest sense includes the whole relationship of physician with his [or 
her] patient’’. Later, the importance of the doctor-patient relationship was described 
by Balint (2) in 1955 as ‘‘the doctor as a drug.’’ In psychotherapy, the quality of the 
treatment relationship is found to shape patient outcomes more strongly than the 
specific techniques applied (3). In primary care, ‘‘knowing the patient is at least as 
important as knowing the disease’’ (4), and physicians with a warm and friendly style 
are more effective than physicians with a more formal style (5). In particular, patient 
satisfaction, treatment adherence, and treatment outcome have been found to be 
associated with the doctor-patient relationship (3,6,7). 
 
A conceptualization of the relationship between the patient and the physician in 
medical care has not yet been clearly articulated. Firstly, Hall et al. (8) considered trust 
as the global attribute of treatment relationships: encompassing subsidiary features, 
such as satisfaction, communication, competency, and privacy. A second concept, 
frequently used in psychotherapy, is the therapeutic or working alliance: the 
collaborative and affective bond between therapist and patient (6,9). According to 
Bordin (9), a good therapeutic working alliance consists of the following three 
elements: agreement on goals, an assignment of tasks, and the development of an 
affective bond between therapist and patient. Thirdly, empathy has been described as 
the key feature in all relationships (10,11). Ridd et al. (12) derived, in their meta-
synthesis, a conceptual framework including all these elements. They characterized the 
patients’ perspective on the depth of the doctor-patient relationship, as a product of 
longitudinal care and consultation experiences, by four main elements: knowledge, 
trust, loyalty, and regard. Each having two sides, the patients’ opinion of the doctor 
and the patients’ perception of the doctor’s opinion about them. 
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Although many different instruments have been developed to assess this relationship, 
the importance of assessing the relationship in scientific research is undervalued. An 
example of its value is the study by van Os et al. (13) who showed that the correct 
application of the depression guideline by general practitioners only improved the 
patient’s well-being when patients valued their relation with their general practitioner 
positively. The large variety in instruments makes it difficult to compare results of 
different studies and to choose which instrument to use in future research. 
 
To be able to choose the adequate instrument, a decision on which aspects of the 
doctor-patient relationship should be measured must be made in advance. In this 
study, we choose to focus solely on the doctor-patient relationship, combined by the 
four elements knowledge, trust, loyalty, and regard (12). Other aspects of the doctor-
patient interaction, such as communication and satisfaction will not be reviewed here. 
Communication assessment instruments have recently been reviewed extensively by 
Boon and Stewart (14). The communicative style of health care providers is known to 
have a strong influence on the appreciation of the doctor-patient relationship (15). 
Nevertheless, the ways in which the concepts of doctor- patient communication and 
relationship are measured are different. Communication questionnaires report on the 
behaviour of the health care provider, that is, communication techniques, both verbal 
and nonverbal. Satisfaction questionnaires report the fulfilment of one’s wishes, 
expectations, or needs, thus making a judgment on past actions. In contrast, 
relationship questionnaires assess the emotions or sentiment elicited by the contact 
between the health care provider and the patient.  
 
To our knowledge there is no (recent) overview of instruments assessing the doctor-
patient relationship. This review aims to provide information and topics for deciding 
about the selection of a specific questionnaire from the instruments available. We 
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performed a systematic review and compared the psychometric characteristics of the 
instruments present. 
 
 
Methods 
 
Search strategy 
In December 2009, we systematically searched for questionnaires measuring the 
doctor-patient relationship. Our inclusion criteria were the following: 1) article about a 
questionnaire or survey; 2) questionnaire measuring the relationship between a health 
care provider and the patient; 3) with the relationship as the main theme of the 
questionnaire, not with satisfaction or communication as the main theme. We 
searched in four databases: PubMed, PsychINFO, EMBASE, andWeb of Science. For 
PubMed our search consisted of the All Fields and MeSH terms for the ‘‘doctor- patient 
relationship,’’ ‘‘therapeutic and working alliance,’’ ‘‘instrument or questionnaire,’’ and 
‘‘psychometrics’’ combined with the Boolean operator AND (the complete search 
string for PubMed is shown in Appendix 1. The search was limited to research on 
‘‘Humans’’ and ‘‘Adults’’ and to the exclusion of letters, editorials, and news items.We 
adapted the search for the other databases as required. There was no language 
restriction. 
 
Selection of publications 
For inclusion we screened titles and abstracts. When title and abstract did not reveal 
sufficient information for inclusion or exclusion, the investigators read the full-text 
publication. Two investigators (R.E. and E.M.) independently included publications 
from the list of retrieved publications. Disagreements about inclusion or exclusion 
were resolved by consulting a third investigator (H.v.R.). Inter-investigator agreement 
on inclusion and exclusion was calculated as kappa; we considered kappa 0.6-0.8 as 
good and kappa 0.8-1.0 as excellent agreement [16]. After inclusion, we checked the 
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references for additional publications. We excluded duplicate citations. No quality 
appraisal was applied because the aim of this study was to make a complete overview 
of the currently existing instruments.  
 
Selection of instruments 
After the initial search we allocated the instruments described in the included studies. 
All instruments were then judged, by three investigators (R.E., E.M., and H.v.R.), to 
consider if they indeed assessed the doctor-patient relationship. This was done by 
scoring each item of the instrument separately as assessing relationship (R), 
satisfaction (S ), communication (C ), or miscellaneous (examples shown in Table 1). 
We considered an instrument to assess the doctor-patient relationship if more than 
half of the items were scored with an ‘‘R.’’ Instruments mainly assessing satisfaction or 
communication were excluded. To be able to provide a comprehensive and up-to-date 
overview of the existing doctor-patient relationship questionnaires, we decided to 
report only on the most recent version or modification of an instrument that has been 
validated; thus combining publications on the same (revised) instruments. We did not 
exclude instruments on the basis of the rater because we believe that the patient, the 
doctor, and the observer all can rate the doctor-patient relationship in their own way. 
Although the relationship between a doctor and a patient could be influenced by the 
general trust in all doctors, we only included instruments assessing the relationship 
with a health care provider.  
 
Description of instruments 
Three investigators (R.E., E.M., and H.v.R.) extracted and registered the data from the 
included studies on standard forms and compared the registration forms. We were not 
blinded for information or authors and journal because we were already well 
acquainted with some of the material. In addition to the data found in the included 
studies, we performed a literature search per instrument to find all published work per 
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instrument. We collected information concerning the content and the psychometric 
characteristics of the instruments. 
 
Table 1. Examples of item appraisal. 
Relationship Communication Satisfaction Miscellaneous 
“I trust my physician” “…discusses options and 
choices…” 
“…content with my 
doctors 
treatment…” 
“the patient self 
observes 
behaviours” 
“…supported me so 
that it was easier 
to deal with my 
illness…” 
“How often does your 
doctor ask how 
family members are 
coping with your 
illness?”  
“How thorough is your 
doctor?”  
“how self-
destructive is 
this patient?” 
“I feel I can count on 
my doctor” 
“…gave an illustrative 
picture of illness…”  
“…cleanliness of the 
waiting room…” 
 
“I feel involved in my 
health care” 
“…made the interaction 
very formal” 
“…ability to get an 
urgent 
appointment…” 
 
“Making you feel at 
ease…” 
“…pays full attention to 
what you are trying 
to tell” 
“…medical skills are not 
as good as they 
should be” 
 
 
 
 
Results 
 
Systematic search 
Our database search retrieved 288 publications and after removing the duplicates, 237 
publications remained to be screened. Two researchers screened independently by 
title and abstract, resulting in the exclusion of 221 publications. The inter-investigator 
agreement was ‘‘good’’ with a kappa of 0.75 (95% confidence interval: 0.63-0.86). 
Reviewing the included publications (n=43) we found a total of 35 instruments as some 
publications reported on the same instrument. Fifteen instruments were excluded; five 
instruments were former versions of another instrument, nine did not meet our 
inclusion criteria after appraisal (less than half of the items scored R), and one was 
unavailable (Projective Test of Dual Communication and Interaction (17)). A flowchart 
is provided in Fig. 1.  
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Figure 1. Selection of instruments 
 
 
In total, we identified and included 19 instruments assessing the doctor-patient 
relationship in this study (18-47). An overview of these instruments is shown in 
appendix 2. An overview of the psychometric properties of each instrument can be 
found in Appendix 3. Fig. 2 shows the item appraisal of the instruments. 
 
 
 
 
Figure 2. Appraisal of instruments 
 
 
Content of the instruments 
Of the 19 instruments found, eight instruments focus on the mental health field. Four 
of these eight instruments have been developed in psychotherapy (Working Alliance 
Inventory [revised short version] [WAI-SR], Agnew Relationship Measure [ARM],  
California Psychotherapy Alliance Scales [CALPAS], and Vanderbilt Therapeutic Alliance 
Scale [VTAS]). Nine instruments have been used in the primary or general health care 
field (Kim Alliance Scale, Stanford Trust in Physician scale [STP], Helping Alliance 
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questionnaire-Revised [HAq-R], patient–physician relationship questionnaire, Patient–
Doctor Relationship Questionnaire [PDRQ-9], Wake Forest (Physician) Trust Scale 
[WFT], Health Care Relationship [HCR] Trust Scale, Consultation and Relational 
Empathy [CARE] Measure, and Difficult Doctor–Patient Relationship Questionnaire 
[DDPRQ-10]). 
 
Other instruments (n=2) focus on a specific health care field, that is, palliative oncology 
(Human Connection scale) and mandated community treatment (Dual-Role 
Relationships Inventory revised version [DRI-R]).  
All instruments state the dimensions aimed to measure or have undergone a factor 
analysis. A great diversity between the dimensions of the instruments is presented. 
The dimension most often mentioned is some form of alliance, containing descriptions 
as bond, goals, tasks, and collaboration. Other instruments frequently mention 
dimensions as ‘‘trust,’’ ‘‘empathy,’’ and ‘‘relational communication.’’ The DDPRQ-10 
measures inverse dimensions because this is a physician-rated instrument developed 
to describe the relationship with the difficult patient. 
 
Almost all instruments are patient rated (n=16), only the VTAS, the RCOS-O, and the 
DDPRQ-10 are not. The VTAS and RCOS-O are observer rated, the DDPRQ-10 is 
physician rated. Some instruments have, besides the patient-rated versions, also a 
physician- or observer-rated version.  
 
Some instruments have been revised various times. The WAI-SR has been frequently 
revised and shortened. Six instruments have one version and have (not yet) been 
revised. These have seldom been used in research articles or are yet to be used by 
others than the creators of the instrument. As shown in Appendix 3, six instruments 
are based on versions of (one or more) other instruments. 
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Psychometric properties of the instruments 
Some instruments have not been completely tested psychometrically; others have 
undergone psychometrical tests vigorously. Most instruments have a known internal 
consistency (Cronbach’s alpha) and some kind of validity tested. Fourteen instruments 
have a Cronbach’s alpha of 0.90 or higher. Four questionnaires have an alpha between 
0.60 and 0.79, of which three subscales, indicating an acceptable internal consistency. 
The questionnaire with the highest overall internal consistency (α=0.95) is the DRI-I 
and has 30 items. The questionnaire with the highest internal consistency on one of 
the subscales is the STAR, which has a Cronbach’s alpha of 0.98 on the subscale 
‘‘positive collaboration.’’ Test-retest reliability is mentioned for seven instruments; the 
inter-rater reliability in only four. 
 
 
Discussion 
 
Our search for instruments assessing the doctor-patient relationship revealed 19 
instruments, assessing various aspects of the doctor-patient relationship. The 
instruments found also vary in terms to which they have been psychometrically tested. 
 
Variety of dimensions 
The variety of aspects assessed by the instruments illustrates the diversity of 
conceptual models used for the doctor-patient relationship. The factors or dimensions 
might vary in such a way that they are not commensurable.  
 
Some of the instruments are developed for use in medical health care disciplines. 
These instruments are frequently based on dimensions as trust (e.g., STP, WFT, and 
HCR) and empathy (e.g., 4-PAS and CARE). In comparison, instruments originating from 
the psychotherapy field focus on the working or therapeutic alliance: the interaction or 
relationship between the therapist and the patient. The patient version of the older 
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36-item version of the WAI and the HAq-I have been found to measure the patient’s 
view of the relationship equivalently (48). Stiles et al. (49) found that the core alliance 
scales of the ARM (Bonds, Tasks, and Goals) are correlated with the WAI scales, 
supporting the assumption that the ARM and the WAI measure some of the same core 
constructs. Also, the CALPAS, the Penn (precursor of the HAq), the Vanderbilt, and the 
WAI have all been found to measure the same construct (50). 
 
The relationship with a physician could be envisioned to differ in comparison to the 
relationship with a psychotherapist, thus explaining the different dimensions assessed. 
However, the instruments originally developed in psychotherapy have also been used 
and validated in medical health care fields. Thus, the doctor-patient relationship must 
have commonalities with the therapist-patient relationship. This can be illustrated by 
comparing the different dimensions and factors with the four constructs of the doctor-
patient relationship by Ridd (knowledge, trust, loyalty, and regard). All the dimensions 
mentioned fit well within this conceptual framework. 
 
Psychometric properties of the instruments 
This overview illustrates the complexness of psychometric testing of questionnaires. 
Internal consistency was mostly tested; in all but one instrument, Cronbach’s alpha 
had been calculated. Other psychometric properties, for example, test-retest reliability 
and inter-rater reliability were not commonly tested; thus making a comparison 
between the instruments on psychometric grounds almost impossible. 
 
Use of instruments 
All instruments are designed for the use in clinical research and not clinical practice. 
The importance of the use of these instruments in clinical research is unambiguous. 
The relationship between the doctor and the patient has been proven to be important 
for (mental) health outcome (3,5). Therefore, it also is an important aspect of medical 
scientific and clinical research, consequently measuring this relationship will add to the 
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validity and reliability of research. If, and how, doctor-patient relationship 
questionnaires could be of use in clinical practice is unclear. They might be able to give 
insight to doctors and therapists in their own relationship with their patient.  
 
Strengths and weaknesses of the study 
To our knowledge, we are the first to provide an overview of the doctor-patient 
relationship assessment instruments. Two independent researchers screened the 
publications for inclusion, with good inter-investigator agreement (kappa 0.75), 
implying that our inclusion and exclusion criteria were clear, which adds rigor to our 
study. The instrument appraisal was done by three researchers, reaching consensus by 
discussion. This strenuous task was done over the course of a couple of weeks to 
remain thorough and decisive. Although beforehand we had decided on the appraisal 
method, this procedure is at risk being arbitrary. Some items of the questionnaires 
might have been classified differently by other researchers. 
 
 
Conclusion 
 
In this review we sought not to find the best instrument but to provide an overview 
giving relevant information to researchers to decide on the best instrument for the 
specific aim of their study. The growing interest in this field has resulted in a large 
number of doctor-patient relationship assessment instruments. We recommend that 
future efforts be aimed at using, refining, and combining existing instruments, instead 
of developing new instruments.  
 
Researchers using a doctor-patient relationship questionnaire should be aware of what 
they are measuring. The suitability of an instrument will depend on the scope of the 
future research. The selection of an instrument should be based on the model or 
conceptual basis of the doctor-patient relationship that is most applicable to the study 
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objectives and the health care field in which it will be applied. In the primary care 
setting, a research instrument is preferably concise and easy to use. The PDRQ is brief 
(nine items) and has an excellent overall internal consistency. 
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Appendices (1-3) 
 
Appendix 1. Search string for PubMed:  
(((((("physician-patient relations"[MeSH Terms] OR ("physician-patient"[All Fields] AND 
"relations"[All Fields]) OR "physician-patient relations"[All Fields] OR ("physician"[All Fields] AND 
"patient"[All Fields] AND "relations"[All Fields]) OR "physician patient relations"[All Fields]) OR 
(doctor-patient[All Fields] AND relationship[All Fields])) OR (patient-doctor[All Fields] AND 
relationship[All Fields])) OR ("professional-patient relations"[MeSH Terms] OR ("professional-
patient"[All Fields] AND "relations"[All Fields]) OR "professional-patient relations"[All Fields] OR 
("professional"[All Fields] AND "patient"[All Fields] AND "relations"[All Fields]) OR "professional 
patient relations"[All Fields])) AND ((("therapeutic alliance"[All Fields] OR "alliance"[All Fields]) 
OR ("trust"[MeSH Terms] OR "trust"[All Fields])) OR ("communication"[MeSH Terms] OR 
"communication"[All Fields]))) AND ((((("test"[All Fields] OR "survey"[All Fields]) OR 
"measurement"[All Fields]) OR "measure"[All Fields]) OR ("weights and measures"[MeSH Terms] 
OR ("weights"[All Fields] AND "measures"[All Fields]) OR "weights and measures"[All Fields] OR 
"scale"[All Fields])) OR ("questionnaires"[MeSH Terms] OR "questionnaires"[All Fields] OR 
"questionnaire"[All Fields]))) AND ("psychometrics"[MeSH Terms] OR "psychometrics"[All Fields] 
OR "psychometric"[All Fields]). 
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ti
o
n
sh
ip
:  
b
as
ed
 o
n
 p
sy
ch
o
an
al
yt
ic
 o
r 
p
an
 
th
eo
re
ti
ca
l c
o
n
ce
p
ts
 in
 t
h
e 
lit
er
at
u
re
 
O
n
ly
 f
o
r 
te
st
in
g 
o
f 
p
sy
ch
o
m
et
ri
c 
p
ro
p
er
ti
e
s 
3
. 
K
im
 A
lli
an
ce
 
Sc
al
e 
(K
A
S)
(1
9
;2
0
) 
 
P
at
ie
n
t 
Fo
u
r 
d
im
e
n
si
o
n
s 
o
f 
al
lia
n
ce
: 
1
) 
co
lla
b
o
ra
ti
o
n
, 2
) 
co
m
m
u
n
ic
at
io
n
, 3
) 
in
te
gr
at
io
n
 a
n
d
 4
) 
em
p
o
w
er
m
en
t 
G
en
e
ra
l h
ea
lt
h
 
ca
re
 
R
ef
in
ed
 v
e
rs
io
n
 o
f 
th
e 
K
im
 A
lli
an
ce
 S
ca
le
 
Fo
u
r 
ke
y 
co
n
ce
p
ts
 o
f 
al
lia
n
ce
 
id
en
ti
fi
e
d
 f
ro
m
 t
h
e 
lit
er
at
u
re
: 
co
lla
b
o
ra
ti
o
n
, c
o
m
m
u
n
ic
at
io
n
, 
in
te
gr
at
io
n
 a
n
d
 e
m
p
o
w
er
m
en
t 
O
n
ly
 f
o
r 
te
st
in
g 
o
f 
p
sy
ch
o
m
et
ri
c 
p
ro
p
er
ti
e
s 
4
. 
D
u
al
-R
o
le
 
R
el
at
io
n
sh
ip
s 
In
ve
n
to
ry
 
re
vi
se
d
 v
er
si
o
n
 
(D
R
I–
R
)(
2
1
) 
 
P
at
ie
n
t/
 
p
h
ys
ic
ia
n
/o
b
se
rv
e
r 
1
) 
C
ar
in
g–
Fa
ir
n
es
s,
 2
) 
Tr
u
st
, 
an
d
 3
) 
To
u
gh
n
e
ss
 
M
an
d
at
e
d
 
co
m
m
u
n
it
y 
tr
ea
tm
en
t 
B
as
ed
 o
n
 t
h
e 
C
A
LP
A
S 
an
d
 t
h
e 
A
R
M
. 
B
as
ed
 o
n
 a
 f
o
cu
s 
gr
o
u
p
 s
tu
d
y 
o
n
 d
u
al
-r
o
le
 r
el
at
io
n
sh
ip
s 
an
d
 
th
er
ap
is
t-
cl
ie
n
t 
re
la
ti
o
n
sh
ip
 
lit
er
at
u
re
 
Ye
s,
 f
o
cu
s 
gr
o
u
p
. 
5
. 
In
p
at
ie
n
t-
Tr
ea
tm
en
t 
A
lli
an
ce
 S
ca
le
 (
I-
TA
S)
(2
2
) 
 
P
at
ie
n
t 
1
) 
b
o
n
d
, 2
) 
go
al
s,
 3
) 
co
lla
b
o
ra
ti
o
n
 
C
lo
se
d
 
p
sy
ch
ia
tr
ic
 w
ar
d
 
B
as
ed
 o
n
 it
em
s 
an
d
 
fa
ct
o
rs
 f
ro
m
 t
h
e 
W
A
I,
 
C
A
LP
A
S 
an
d
 H
A
Q
. 
B
as
ed
 o
n
 t
h
e 
lit
er
at
u
re
 o
n
 
th
er
ap
eu
ti
c 
al
lia
n
ce
: t
h
e 
co
lla
b
o
ra
ti
ve
 a
n
d
 a
ff
ec
ti
ve
 
b
o
n
d
 b
e
tw
ee
n
 t
h
er
ap
is
ts
 a
n
d
 
p
at
ie
n
t 
O
n
ly
 f
o
r 
te
st
in
g 
o
f 
p
sy
ch
o
m
et
ri
c 
p
ro
p
er
ti
e
s 
6
. 
St
an
fo
rd
 T
ru
st
 
in
 P
h
ys
ic
ia
n
 
sc
al
e 
(S
TP
) 
(2
3
-
2
5
) 
P
at
ie
n
t 
O
n
e 
tr
u
st
 c
o
n
st
ru
ct
 w
it
h
 
th
re
e 
d
im
e
n
si
o
n
s:
  
1
. d
ep
e
n
d
ab
ili
ty
 o
f 
th
e 
p
h
ys
ic
ia
n
, 2
. c
o
n
fi
d
en
ce
 in
 
th
e 
p
h
ys
ic
ia
n
, 3
. 
G
en
e
ra
l h
ea
lt
h
 
ca
re
  
- 
B
as
ed
 o
n
 li
te
ra
tu
re
: t
ru
st
 is
 
d
ef
in
ed
 a
s 
th
e 
p
at
ie
n
ts
 b
e
lie
f 
th
at
 t
h
e 
p
h
ys
ic
ia
n
's
 w
o
rk
s 
an
d
 
ac
ti
o
n
s 
ar
e 
cr
ed
ib
le
 a
n
d
 c
an
 b
e 
re
lie
d
 u
p
o
n
.  
Ye
s,
 f
o
cu
s 
gr
o
u
p
. 
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co
n
fi
d
en
ti
al
it
y 
an
d
 r
el
ia
b
ili
ty
 
o
f 
in
fo
rm
at
io
n
 
 
7
. 
W
o
rk
in
g 
A
lli
an
ce
 
In
ve
n
to
ry
 
(r
ev
is
ed
 s
h
o
rt
 
ve
rs
io
n
) 
(W
A
I-
SR
)e
.g
. (2
6
;2
7
) 
 
P
at
ie
n
t 
W
o
rk
in
g 
al
lia
n
ce
: 1
) 
go
al
s,
 2
) 
ta
sk
, 3
) 
b
o
n
d
 
P
sy
ch
o
th
er
ap
y 
 
W
o
rk
in
g 
A
lli
an
ce
 
In
ve
n
to
ry
 (
W
A
I)
 a
n
d
 
W
o
rk
in
g 
A
lli
an
ce
 
In
ve
n
to
ry
 S
h
o
rt
 (
W
A
I-
S)
.  
B
as
ed
 o
n
 B
o
rd
in
's
 m
o
d
el
 o
f 
al
lia
n
ce
, t
h
e 
b
o
n
d
-t
as
k-
go
al
 
m
o
d
el
 (
th
re
e-
fa
ct
o
r 
m
o
d
el
) 
 
O
n
ly
 in
 t
h
e 
d
ev
el
o
p
m
e
n
t 
o
f 
th
e 
p
re
cu
rs
o
r 
fo
r 
te
st
in
g 
o
f 
p
sy
ch
o
m
et
ri
c 
p
ro
p
er
ti
e
s 
8
. 
H
el
p
in
g 
A
lli
an
ce
 
q
u
es
ti
o
n
n
ai
re
-
R
ev
is
ed
(H
A
q
-
R
)(
2
8
-3
0
) 
 
P
at
ie
n
t 
Th
er
ap
eu
ti
c 
al
lia
n
ce
: 1
) 
co
o
p
er
at
io
n
 a
n
d
 2
) 
h
el
p
fu
ln
es
s 
G
en
e
ra
l h
ea
lt
h
 
ca
re
 
1
1
-i
te
m
 H
A
q
-I
; w
h
ic
h
 
w
as
 o
ri
gi
n
al
ly
 p
ar
t 
o
f 
th
e 
P
en
n
 H
el
p
in
g 
A
lli
an
ce
 S
ca
le
s.
  
B
as
ed
 o
n
 t
h
e 
co
n
ce
p
t 
o
f 
'h
el
p
in
g 
al
lia
n
ce
'. 
Th
e 
tw
o
 
fa
ct
o
rs
 't
ra
n
sf
er
en
ce
' a
n
d
 
's
ym
p
at
h
et
ic
 u
n
d
e
rs
ta
n
d
in
g'
 
ar
e 
im
p
o
rt
an
t.
 
N
o
 
9
. 
A
gn
ew
 
R
el
at
io
n
sh
ip
 
M
ea
su
re
 
(A
R
M
)(
3
1
) 
 
P
at
ie
n
t 
/ 
th
er
ap
is
t 
1
) 
b
o
n
d
, 2
) 
p
ar
tn
er
sh
ip
, a
n
d
 
3
) 
co
n
fi
d
en
ce
, o
p
en
n
es
s 
P
sy
ch
o
th
er
ap
y 
B
as
ed
 o
n
 c
o
n
st
ru
ct
s 
o
f 
th
e 
C
A
LP
A
S,
 H
A
Q
, 
an
d
 W
A
I.
 
B
as
ed
 o
n
 t
h
e 
lit
er
at
u
re
 o
n
 t
h
e 
al
lia
n
ce
 c
o
n
st
ru
ct
s,
 a
d
d
in
g 
th
at
 
th
er
ap
eu
ti
c 
al
lia
n
ce
 m
u
st
 n
o
t 
re
fl
ec
t 
a 
th
e
ra
p
e
u
ti
c 
te
ch
n
iq
u
e 
o
r 
o
u
tc
o
m
e.
 
O
n
ly
 f
o
r 
te
st
in
g 
o
f 
p
sy
ch
o
m
et
ri
c 
p
ro
p
er
ti
e
s 
1
0
. 
C
al
if
o
rn
ia
 
P
sy
ch
o
th
er
ap
y 
A
lli
an
ce
 S
ca
le
s 
(C
A
LP
A
S)
(3
2
;3
3
) 
P
at
ie
n
t/
 
th
er
ap
is
t 
/ 
o
b
se
rv
er
 
1
) 
p
at
ie
n
t 
co
m
m
it
m
en
t,
 2
) 
p
at
ie
n
t 
w
o
rk
in
g 
ca
p
ac
it
y,
 3
) 
th
er
ap
is
t 
u
n
d
er
st
an
d
in
g 
an
d
 
in
vo
lv
em
en
t,
 4
) 
w
o
rk
in
g 
st
ra
te
gy
 c
o
n
se
n
su
s.
 
P
sy
ch
o
th
er
ap
y 
B
as
ed
 o
n
 a
lli
an
ce
 
m
ea
su
re
s 
d
ev
el
o
p
ed
 
at
 t
h
e 
La
n
gl
ey
 P
o
rt
er
 
P
sy
ch
ia
tr
ic
 in
st
it
u
te
 
(C
A
LT
A
R
S)
 
Th
eo
re
ti
ca
lly
 d
er
iv
ed
 m
ea
su
re
 
o
f 
al
lia
n
ce
. 
O
n
ly
 f
o
r 
te
st
in
g 
o
f 
p
sy
ch
o
m
et
ri
c 
p
ro
p
er
ti
e
s 
1
1
. 
Th
e 
p
at
ie
n
t-
p
h
ys
ic
ia
n
 
re
la
ti
o
n
sh
ip
 
q
u
es
ti
o
n
n
ai
re
 
(P
P
R
Q
)(
3
4
) 
P
at
ie
n
t 
1
) 
kn
o
w
le
d
ge
 o
f 
p
at
ie
n
ts
; 2
) 
co
m
p
et
en
ce
; 3
) 
au
to
n
o
m
y 
su
p
p
o
rt
; 4
) 
tr
u
st
 in
 p
h
ys
ic
ia
n
 
ad
h
er
en
ce
; 5
) 
re
la
ti
o
n
sh
ip
 
co
m
m
it
m
en
t;
 6
) 
h
ea
lt
h
y 
ea
ti
n
g 
b
eh
av
io
u
r;
 7
) 
p
re
se
n
ce
 
G
en
e
ra
l h
ea
lt
h
 
ca
re
 
N
ew
ly
 d
ev
e
lo
p
ed
 
it
em
s 
in
 c
o
m
b
in
at
io
n
 
w
it
h
 e
xi
st
in
g 
it
em
s 
fr
o
m
 t
h
e 
P
ri
m
ar
y 
C
ar
e 
A
ss
es
sm
en
t 
Su
rv
ey
, H
ea
lt
h
 C
ar
e 
B
as
ed
 o
n
 o
w
n
 m
o
d
el
: P
at
ie
n
ts
’ 
tr
u
st
 o
f 
th
e
ir
 p
h
ys
ic
ia
n
 is
 
as
so
ci
at
ed
 w
it
h
 3
 
co
m
p
o
si
te
 p
h
ys
ic
ia
n
 b
e
h
av
io
rs
: 
d
ev
el
o
p
in
g 
kn
o
w
le
d
ge
 o
f 
th
e 
p
at
ie
n
t,
 d
em
o
n
st
ra
ti
n
g 
m
ed
ic
al
 
N
o
 
208729-L-bw-Eveleigh
.  
o
f 
ch
ro
n
ic
 il
ln
es
s 
C
lim
at
e 
Q
u
e
st
io
n
n
ai
re
, 
G
en
e
ra
l A
d
h
er
en
ce
 
Sc
al
e,
 
co
m
p
et
en
ce
, a
n
d
 s
u
p
p
o
rt
in
g 
p
at
ie
n
t 
au
to
n
o
m
y 
1
2
. 
P
at
ie
n
t-
D
o
ct
o
r 
R
el
at
io
n
sh
ip
 
Q
u
e
st
io
n
n
ai
re
 
(P
D
R
Q
-9
) 
(3
5
;3
6
) 
 
P
at
ie
n
t 
1
) 
em
p
h
at
ic
 s
ty
le
 a
n
d
 2
) 
av
ai
la
b
ili
ty
 
G
en
e
ra
l h
ea
lt
h
 
ca
re
 
D
er
iv
ed
 f
ro
m
 o
f 
th
e 
H
el
p
in
g 
A
lli
an
ce
 
Q
u
e
st
io
n
n
ai
re
 
Se
e 
H
A
Q
 
N
o
 
1
3
. 
Th
e 
re
la
ti
o
n
al
 
co
m
m
u
n
ic
at
io
n
 
sc
al
e 
fo
r 
o
b
se
rv
er
s:
 R
C
S-
O
(3
7
;3
8
) 
O
b
se
rv
er
 
Th
e 
re
la
ti
o
n
al
 c
o
m
p
o
n
e
n
t 
o
f 
d
o
ct
o
r 
p
at
ie
n
t 
in
te
ra
ct
io
n
: 
1
)i
m
m
ed
ia
cy
/a
ff
ec
ti
o
n
;  
2
) 
si
m
ila
ri
ty
/ 
d
ep
th
; 
3
)r
ec
ep
ti
vi
ty
/ 
tr
u
st
; 4
) 
co
m
p
o
su
re
; 5
) 
fo
rm
al
it
y;
 6
) 
d
o
m
in
an
ce
 
M
ed
ic
al
 t
ra
in
in
g 
Th
e 
re
la
ti
o
n
al
 
co
m
m
u
n
ic
at
io
n
 s
ca
le
 
b
y 
B
u
rg
o
o
n
 a
n
d
 H
al
e 
w
as
 a
d
ap
te
d
 f
o
r 
u
se
 
as
 a
n
 o
b
se
rv
at
io
n
al
 
in
st
ru
m
en
t 
b
y 
th
ir
d
 
p
ar
ty
 r
at
er
s.
 
B
u
rg
o
o
n
 a
n
d
 H
al
e 
(1
9
8
4
) 
co
n
ce
p
tu
al
iz
ed
 r
el
at
io
n
al
 
co
m
m
u
n
ic
at
io
n
 a
s 
th
e 
ve
rb
al
 
an
d
 n
o
n
ve
rb
al
 t
h
em
es
 p
re
se
n
t 
in
 p
eo
p
le
's
 c
o
m
m
u
n
ic
at
io
n
 t
h
at
 
d
ef
in
e 
an
 in
te
rp
er
so
n
al
 
re
la
ti
o
n
sh
ip
. 
 N
o
 
1
4
. 
W
ak
e 
Fo
re
st
 
(P
h
ys
ic
ia
n
) 
Tr
u
st
 S
ca
le
 
(W
FT
)e
.g
. (
8;
39
)  
P
at
ie
n
t 
Tr
u
st
 in
 p
h
ys
ic
ia
n
: 1
) 
tr
u
st
 
an
d
 2
) 
d
is
tr
u
st
 
G
en
e
ra
l h
ea
lt
h
 
ca
re
 
- 
 
A
 c
o
n
ce
p
tu
al
 m
o
d
e
l w
as
 
d
ev
el
o
p
e
d
 a
ft
er
 a
 r
ev
ie
w
 o
f 
th
e 
lim
it
ed
 t
h
eo
re
ti
ca
l 
lit
er
at
u
re
 in
 m
ed
ic
al
 s
et
ti
n
gs
 
an
d
 t
h
e 
ex
te
n
si
ve
 t
h
eo
re
ti
ca
l 
an
d
 e
m
p
ir
ic
al
 li
te
ra
tu
re
 in
 
n
o
n
m
ed
ic
al
 s
et
ti
n
gs
. P
at
ie
n
t 
tr
u
st
 a
s 
h
av
in
g 
fi
ve
  
d
o
m
ai
n
s:
 (
1
) 
fi
d
el
it
y,
 (
2
) 
co
m
p
et
en
ce
, (
3
) 
h
o
n
es
ty
, (
4
) 
co
n
fi
d
en
ti
al
it
y,
 (
5
) 
gl
o
b
al
 t
ru
st
. 
 N
o
 
1
5
. 
H
ea
lt
h
 C
ar
e 
R
el
at
io
n
sh
ip
 
(H
C
R
) 
Tr
u
st
 
Sc
al
e(
4
0
) 
P
at
ie
n
t 
1
) 
In
te
rp
er
so
n
al
 c
o
n
n
ec
ti
o
n
, 
2
) 
re
sp
ec
tf
u
l c
o
m
m
u
n
ic
at
io
n
 
3
) 
p
ro
fe
ss
io
n
al
 p
ar
tn
er
in
g 
G
en
e
ra
l h
ea
lt
h
 
ca
re
 
- 
B
as
ed
 o
n
 p
at
ie
n
t 
as
se
ss
m
en
t 
o
f 
d
o
ct
o
rs
' c
o
m
m
u
n
ic
at
io
n
  a
n
d
 
re
la
ti
o
n
al
 e
m
p
at
h
y 
in
 t
h
e 
co
n
su
lt
at
io
n
 
 
Ye
s,
 f
o
cu
s 
gr
o
u
p
. 
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1
6
. 
C
o
n
su
lt
at
io
n
 
an
d
 R
el
at
io
n
al
 
Em
p
at
h
y 
(C
A
R
E)
 
M
ea
su
re
(1
1
;4
1
-
4
3
) 
P
at
ie
n
t 
R
el
at
io
n
al
 e
m
p
at
h
y 
G
en
e
ra
l h
ea
lt
h
 
ca
re
 
- 
Th
e 
it
em
s 
in
 t
h
e 
C
A
R
E 
M
ea
su
re
 
w
er
e 
d
ev
e
lo
p
ed
 b
o
th
 o
n
 
th
eo
re
ti
ca
l g
ro
u
n
d
s,
 li
te
ra
tu
re
 
re
vi
ew
, a
n
d
 q
u
al
it
at
iv
e 
in
te
rv
ie
w
s 
w
it
h
 p
at
ie
n
ts
. 
 
Ye
s.
 
1
7
. 
Sh
o
rt
 f
o
rm
 
V
an
d
er
b
ilt
 
Th
er
ap
eu
ti
c 
A
lli
an
ce
 S
ca
le
 
(s
f-
V
TA
S)
(4
4
) 
O
b
se
rv
er
 
Th
er
ap
eu
ti
c 
al
lia
n
ce
: 1
) 
go
al
s,
 
2
) 
ta
sk
, 3
) 
b
o
n
d
 
P
sy
ch
o
th
er
ap
y 
V
TA
S 
an
d
 V
TA
S-
re
vi
se
d
. 
Th
er
ap
eu
ti
c 
al
lia
n
ce
 a
s 
d
es
cr
ib
ed
 b
y 
B
o
rd
in
. 
Ye
s 
1
8
. 
D
if
fi
cu
lt
 D
o
ct
o
r-
P
at
ie
n
t 
R
el
at
io
n
sh
ip
 
Q
u
e
st
io
n
n
ai
re
 
(D
D
P
R
Q
-1
0
)(
4
5
) 
P
h
ys
ic
ia
n
 
1
) 
Th
e 
d
em
an
d
in
g 
ir
ri
ta
ti
n
g 
p
at
ie
n
t,
 2
) 
p
h
ys
ic
ia
n
 
d
ys
p
h
o
ri
a,
 3
) 
co
m
p
lia
n
ce
 a
n
d
 
co
m
m
u
n
ic
at
io
n
, 4
) 
th
e 
se
lf
-
d
es
tr
u
ct
iv
e 
p
at
ie
n
t,
 5
) 
th
e 
se
d
u
ct
iv
e 
p
at
ie
n
t.
 
P
ri
m
ar
y 
ca
re
 
- 
B
as
ed
 o
n
 t
h
e 
au
th
o
rs
’ c
lin
ic
al
 
ex
p
er
ie
n
ce
 a
n
d
 t
h
eo
re
ti
ca
l 
m
o
d
el
s 
fo
u
n
d
 in
 t
h
e 
lit
er
at
u
re
. 
G
ro
ve
s’
 d
es
cr
ip
ti
o
n
 o
f 
th
e 
“h
at
ef
u
l p
at
ie
n
t”
 s
er
ve
d
 a
s 
an
 
im
p
o
rt
an
t 
co
n
ce
p
tu
al
 
fo
u
n
d
at
io
n
. 
 
Ye
s,
 b
o
th
 
d
o
ct
o
rs
 a
n
d
 
p
at
ie
n
ts
.  
1
9
. 
Sc
al
e 
To
 A
ss
es
s 
th
er
ap
eu
ti
c 
R
el
at
io
n
sh
ip
 
(S
TA
R
)(
4
6
) 
 
P
at
ie
n
t/
 
p
h
ys
ic
ia
n
 
1
) 
p
o
si
ti
ve
 c
o
lla
b
o
ra
ti
o
n
 a
n
d
 
2
) 
p
o
si
ti
ve
 c
lin
ic
ia
n
 in
p
u
t 
in
 
b
o
th
 v
er
si
o
n
s,
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Summary 
Changing inappropriate long-term antidepressant use is complex and difficult. 
Resistance to change is prominent, either when undertreated or over-treated. A gap 
exists between guidelines and clinical practice. Patients see little need to discontinue 
their antidepressant, even when an indication for further use is absent. GPs face the 
challenge to focus on patient-centred care and the doctor-patient relationship, as well 
as preventing over-medicalization. 
Antidepressant prescriptions have increased exponentially over the last decades in 
primary care. This is mostly due to longer duration of use. Long-term antidepressant 
use is not always appropriate. Patients can be under-treated, i.e. psychiatric symptoms 
persist despite maintenance therapy with antidepressants, or over-treated, i.e. long-
term use of antidepressants is continued although there is no indication anymore.  
In chapter 2 we discussed the design of the PANDA study, a cluster randomized 
controlled clinical trial with the aim to reduce inappropriate long-term antidepressant 
use. Participants were long-term antidepressant users (>9 months use), who according 
to clinical guidelines were inappropriate long-term users. We divided these patients is 
two groups, an over-treatment group and an under-treatment group. Both groups 
were randomized to receive either care as usual or our intervention. The intervention 
consisted of a letter to the patients’ GP stating the inappropriateness of the 
antidepressant usage, disclosure of the current psychiatric diagnosis and a patient-
tailored treatment advice. For the overtreatment trial this advice consisted of an 
advice to discontinue the use of the antidepressant, together with a tapering scheme 
and information on the discontinuation syndrome. For the under-treatment trial this 
consisted of disclosure of the current psychiatric diagnosis combined with a patient-
tailored treatment recommendation. 
We demonstrated the complexity of inappropriate long-term antidepressant usage in 
chapter 3. A large amount of long-term antidepressant users was found to possibly be 
208729-L-bw-Eveleigh
Prescribing Antidepressants Appropriately 
 
119 
using these drugs inappropriately, but participation rates were disappointing. In the 
over-treatment trial it proved to be difficult to discontinue long-term antidepressant 
medication, despite the lack of a proper indication for the repeat prescriptions. 
Patients and also their GPs were reluctant to accept the discontinuation advice, and 
only few actually successfully discontinued their medication. Next to this, the cessation 
advice seemed to result in larger relapse risks but surprisingly this was not associated 
with antidepressant discontinuation.  
In chapter 3 we also found a low number of patients using long-term antidepressants 
who were under-treated, i.e. persistent psychiatric symptoms despite maintenance 
therapy with antidepressants. Whether this was due to a low prevalence or due to 
recruitment bias remains unclear. The numbers were too small to be able to ascertain 
the effectiveness of our intervention accurately. Again, we found a large resistance to 
the given recommendation, with half of the patients and their GPs refusing to take the 
next step to possibly achieve remission. 
The cost-utility analysis of the PANDA study was presented in chapter 4. Here, the 
discontinuation advice resulted in a reduction of societal costs, more specifically a 
reduction in productivity losses, with no difference in the quality of life (QALY).  We 
hypothesized that this result was due to loss of stigma en to patient empowerment 
caused by the discontinuation advice. Even when patients did not stop using their 
antidepressant, they apparently did change something that resulted in the reduction 
of productivity losses. 
Our qualitative study on the barriers and facilitators of discontinuing long-term 
antidepressant use in chapter 5 provided more understanding of patients’ attitudes in 
this complex matter. The most apparent barrier was the notion that antidepressants 
are necessary to supply the deficient serotonin. Fear (of recurrence, relapse or to 
disturb the equilibrium) was also prominent and prior attempts fuelled these 
anticipations. Facilitators to discontinue were information about limited duration of 
usage given at the time of starting the drug and confidence in a successful attempt 
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increased by a supporting GP. Patients felt that being able to live without their 
antidepressants empowered them.  Next to the barriers and facilitators, we also found 
ambivalence towards the antidepressant use.  
To be able to incorporate the influence of the doctor-patient relationship on the 
treatment of patients using long-term antidepressant we conducted a systematic 
review in Chapter 6. This resulted in an overview of 19 questionnaires assessing the 
doctor-patient relationship. The doctor-patient relationship has been linked to patient 
satisfaction and to treatment adherence and outcome. Different models and concept 
are used to assess this relationship. In the PANDA-study the PDRQ was used. In the 
discontinuation process, the doctor-patient relationship is of importance. In our 
PANDA trial, unfortunately we found too little numbers of patient who discontinued 
their long-term antidepressant to make use of the PDRQ and look into the confounding 
influence this relationship had on the effectiveness of our discontinuation advice.  
  
208729-L-bw-Eveleigh
 
 
Chapter 8.  
 
General discussion and clinical implications 
  
208729-L-bw-Eveleigh
Chapter 8. General discussion and clinical implications 
 
122 
Summary 
 
The aim of this thesis was to provide insight into long-term antidepressant use in 
primary care and to evaluate an intervention to reduce inappropriate long-term 
prescriptions, considering both over-treatment and under-treatment. We performed a 
cluster randomized controlled clinical trial to evaluate the impact of a cessation advice 
to the GP in order to reduce overtreatment with antidepressants in general practice. 
We demonstrated the difficulty to discontinue inappropriate long-term antidepressant 
use. Only 10 of the 146 patients with inappropriate long-term use of antidepressants 
successfully stopped in the year of the study (irrespective of the intervention). A 
prominent finding was that half of the patients and GPs in the PANDA study declined 
the recommendation to discontinue their antidepressant use, refusing even to give it a 
try. In our cost-utility analysis, we found that the antidepressant cessation advice did 
result in a modest reduction of societal costs. This reduction in costs was mostly due to 
reduction of productivity losses, possibly due to patient empowerment and loss of 
stigma. 
 
In addition to the over-treatment with long-term antidepressants, we found a small 
number of patients being under-treated amongst the participating long-term 
antidepressant users in primary care, in contrast to the literature (1-3). In this group, 
the patient-and-diagnosis-tailored advice given in the trial were again declined 
frequently (59%).  
 
Our search for instruments assessing the doctor-patient relationship revealed 19 
instruments, assessing various aspects of the doctor-patient relationship. We 
incorporated one (PDRQ) in the PANDA study (4), but unfortunately we found too few 
patients who discontinued their long-term antidepressant to be able to evaluate the 
PDRQ and look into the confounding influence of this relationship on successful 
discontinuation of antidepressants. 
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Outline of discussion 
 
Below, the results of this thesis will be discussed in a broader perspective. First, we will 
discuss the ‘resistance to change’, by taking a dogmatic perspective of the evidence-
based guidelines. For a further understanding to antidepressant prescriptions in 
primary care, we will discuss the diagnosis of depression in primary care, followed by 
an outline of the history of treating stress and the changed perceptions to 
antidepressant use in the recent past. Next, we will discuss the role of the doctor-
patient relationship and the dynamics between evidence-based guidelines and this 
relationship. Consequently, giving a more and deeper understanding of the ‘resistance 
to change again’. Then, the limitations of this thesis will be addressed. We will 
conclude with the clinical implications of this thesis and suggestions for further 
research.  
 
 
 
Resistance to change: a dogmatic perspective 
 
When taking a dogmatic perspective, the clinical guidelines are considered to be the 
‘truth’ and adherence to these guidelines in the patients and GPs best interest. An 
overall finding of the PANDA-study was an apprehension to change. The study was 
aimed to improve care for patients using antidepressants long-term, by improving 
adherence to the current guidelines for depressive and anxiety disorders. The 
apprehension to change was found in both patients and GPs.  
The recruitment of patients using long-term antidepressants proved difficult. Only 
approximately 15% of the eligible patients consented to participate in this study. With 
only few patients willing to participate, a gap became apparent between perceived 
self-interest (by the patient) and professionally perceived patient-interest. Even when 
willing to participate, a large number of patients were reluctant to comply with the 
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provided treatment recommendation in this study. The results from interviews with 
over-treated patients showed a lack of motivation to discontinue their 
antidepressants. However, the assumptions underlying this reluctance were not 
always correct, such as the conceptualisation of depression as a chronic disease and 
resulting from a deficiency in serotonin (Chapter 5). Also in the case of under-
treatment, perceptions between patients and professional differ: patients suffering 
from depressive symptoms have been found to be content with ‘suboptimal’ care, not 
willing or deserving to take up the doctor’s time (5), and treatment outcomes (such as 
remission) have been found to not always be the same as patients goals (6).  
Participating GPs were also reluctant to accept the given treatment recommendations, 
despite that these recommendations were based on their own (evidence-based) 
guidelines. Our intervention, in addition to not being able to motivate patients to 
change, did not appear to be sufficient to motivate GPs to change their inappropriate 
long-term antidepressant prescriptions, possibly because they feared this would be too 
time consuming or would conflict with other priorities.  Maybe GPs did not feel 
adequately trained or informed to discuss the recommendation. However, the time 
needed for our intervention was minimal. We provided the GP with the current 
psychiatric diagnosis or the lack of a current diagnosis, and with a detailed treatment 
advice. Information on tapering antidepressants and the antidepressant 
discontinuation syndrome was provided via an information leaflet. In case of under-
treatment, the GP was provided with information on the recommended psychological 
treatment, i.e. cognitive therapy or interpersonal therapy. Educating GPs further on 
long-term antidepressant usage, the indications and also the risks and adverse effects 
of inappropriate long-term use, might have made our intervention more effective. GPs 
need to be able to motivate patients to change, which requires  good communication 
skills on the part of the GPs to help overcome the barriers patients perceive. 
 
 
Diagnosing depression in primary care 
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To discuss over-treatment with antidepressants it is important to first look at the main 
indication for these drugs: depression. The diagnosis of depression in primary care has 
been debated widely (7-9). The focus was first on the under-diagnosis of this disorder 
in primary care (2). Evidence from psychiatric care was brought to primary care. 
However, the same set of symptoms will have a lower predictive value in primary care 
compared to secondary care, as the prevalence of severe depressive disorders is 
proportionally lower. In addition, depression in primary care overlaps with a wide 
range of common physical diagnoses and medically unexplained symptoms (10). Some 
authors question if we are turning troubled people into patients; turning normal 
sadness and misery into a DSM classified disorder (8). Even when adhering to the DSM 
criteria, substantial symptom variation is found between patients all qualifying for the 
same diagnosis of a major depressive disorder, acknowledging the importance of 
individual patient context (11). For primary care it is just as important to prevent 
medicalization as it is to provide appropriate care (12). Research has even suggested 
that people whose depressive symptoms remain undetected by their physician, have a 
better prognosis than those diagnosed with depression (13).  Also, diagnosing 
depression has been seen as potentially harmful, by increasing stigma and lowering 
patient empowerment (14).  GPs acknowledge this: GPs preferred to use a model 
based on aetiological and contextual thinking, attributing depression mainly to a 
reaction to circumstances and most preferred strategies to diagnose depression are 
ruling out somatic causes, watchful waiting and empowering patients (15). 
 
History of treating stress 
 
Anxiety and depressive symptoms have always existed, and physicians have used 
diverse substances for thousands of years to treat these symptoms. From purgative 
and laxative agents, betel nuts, marijuana and alcohol, to sedatives and analgesics. By 
the 19
th
 century opium and morphine were commonly used, later followed by 
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sedatives and tranquilizers. Benzodiazepines were popular medicines in the 1950’s and 
1960’s. As a result of this popularity and explosive use, concerns were raised about the 
over-prescription of these drugs and prescriptions were more restricted. Then the 
selective serotonin reuptake inhibitors (SSRI’s) were introduced, promising fewer side 
effects and less monitoring requirements compared to older antidepressive agents. 
Again, it seems that these new drugs have been overvalued and uncritically used in the 
same enthusiastic way as the benzodiazepines in the past. This pattern of enthusiastic 
introduction of new medicines followed by concerns and critical evaluation of the 
same medication, is not new and not confined to psychiatric medication, e.g. new 
antidiabetic drugs, statines (16-18). With the introduction of new drugs, GPs are 
nowadays becoming more conservative and more critical towards new drugs and 
prescribe less (19).  
 
Antidepressants reconsidered 
 
Prescribing antidepressants for longer than suggested in the multidisciplinary 
guidelines should be reconsidered, also in view of the long-term adverse effects. With 
research suggesting that long-term antidepressant use could paradoxically induce 
depression (20, 21), physician should take caution: ‘Primum non nocere’. 
The specificity of the effects of antidepressant medication is being questioned by 
increasing evidence of placebo effects of these drugs (22). The difference between 
placebo and antidepressants was found to be statistically significant, but also of low 
clinical relevance (23, 24). In addition, short-term psychological treatment, such as 
interpersonal psychotherapy, cognitive therapy and problem solving treatment have 
been found to be equally effective as antidepressants in primary care (25, 26). 
Moreover, many patients prefer psychological treatment over medication (27). 
However, patients are still more likely to receive antidepressant treatment (28). Once 
prescribed, there is sufficient evidence to support the recommendation to continue 
antidepressants for at least 6 to 12 months after initial response to prevent relapse 
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and recurrence (29), but after a single depressive episode there is no evidence for 
longer duration of treatment (30). Regular medication review is advised, and 
antidepressant medication should be discontinued when there is no indication 
anymore (31-33). This thesis shows that it is not easy to persuade both patients and 
GPs to do so. 
 
Flexibility, the doctor-patient relationship and changing again 
 
Shared decision making and personalized healthcare are the cornerstones of primary 
care, and too rigidly applied guidelines can limit patient choice and may damage the 
doctor–patient relationship. GPs need flexibility in order to optimise the 
implementation of guidelines, while responding to individuals' needs and preferences 
(34).  By repeated criticisms concerning under-treatment, antidepressants were 
prescribed more frequently (2). Now, guidelines require GPs to change again by 
conversely criticizing their antidepressant (over)prescriptions. It is conceivable that the 
GPs in the PANDA study did not agree with the content of the advice, or could not 
conform easily to new insight after first conforming to the promotion of 
antidepressants, thus ‘changing again’. 
 
During the changed perceptions of the use of antidepressants in the treatment of 
depression, the doctor-patient relationship has remained an important constant factor 
in primary health care (35). The primary care setting is critical to achieve a sustainable 
doctor-patient relationship (36, 37).  Patients prefer to consult their own GP when 
suffering from depressive symptoms (38). Next to this, the doctor-patient relationship 
has been found to be associated with adherence to antidepressant treatment and to 
what extent patients with depression improve (39). GPs value this relationship 
accordingly. We speculate that the resistance to the recommendation could be 
explained as standing by their patient in the decision to decline the prospect of 
withdrawing from antidepressants and savour this relationship. 
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The dynamics of changing guidelines also affect patients. Despite patients primarily 
preferring psychological treatment (27), guidelines first promoted antidepressants. 
After accepting these drugs and finding an emotional balance, these drugs became a 
part of their lives (Chapter 5) (40). The PANDA-study now required them to change 
their perceptions again and discontinue the drugs they were convinced to need. From 
this perspective, the poor efficacy of the intervention in the PANDA-study can be seen 
as the consequence of patients’ changed health beliefs: led by ‘evidence-based 
guidelines’, patients were able to accept the benefits of antidepressants and the ratio 
behind it. But once patients have moved away from their preference for advice, 
counselling and psychological treatment, it is less likely that they will move back to 
their initial beliefs.     
 
Limitations 
 
Of course, the studies conducted in this thesis have their limitations. In each chapter, 
specific limitations have been addressed. General limitations concerning this thesis will 
be discussed below. 
To conduct the PANDA-study it was necessary to approach a large number of long-
term antidepressant users to be able to enrol sufficient participants. This is a 
limitation, but a result as well. The willingness to participate could be seen as a 
potential willingness to change, thus the results could underestimate the resistance to 
change in the total population of long-term antidepressant users. In addition, one 
could conceive that the low participation rate also reflects stigma and shame of 
patients using antidepressants long-term and did not want to discuss their 
antidepressant use. On the other hand, participation in mental health research is 
known to be troublesome (41). The generalizability of our results therefore does 
remain of some concern. 
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The outcome measures used in the PANDA-study are based on the DSM, and as 
discussed above the usability of the DSM criteria for primary care could be disputed. 
The clinical guidelines are based on these criteria and our intervention was based on 
adherence to these guidelines. This resembles the gap between guidelines and clinical 
practice in primary care. The assumption that the guidelines (and thus our 
intervention) direct to the best possible care has been questioned: maybe we need to 
alter the guidelines to fit the needs of the GPs and patients (42, 43)? 
 
Clinical implications 
 
We would like to offer the following suggestions to facilitate future discontinuation 
attempts at first prescription.  When patients anticipate a limited duration of use, both 
compliance at start and willingness to discontinue in the future will be facilitated. In 
addition, the ‘serotonin-story’ should be avoided as explanation for the efficacy of 
antidepressants. A serotonin deficiency may not even exist (44). We suggest a more 
multi-factorial explanation, were antidepressants may have a role in facilitating 
recovery but are not a cure of a deficiency. 
 
It has been found that the frequency of reviewing long-term use of antidepressants 
decreases over time (45, 46).  Regular medication review could possibly prevent 
inappropriate continued repeat prescriptions (47). In both cases of over-treatment and 
under-treatment, regular review should improve the quality of care. In these visits 
doctors should discuss psychological symptoms and consider the possibility of 
discontinuing the medication. The decision to start tapering should be shared decision 
between doctor and patient.  
In our qualitative research following the PANDA study we found a diversity of patients’ 
needs during the discontinuation of antidepressant medication. For the patient it is 
important that they receive sufficient information about the pros and cons of their use 
of antidepressant, to be able to reach a decision whether to discontinue. Knowledge 
208729-L-bw-Eveleigh
Chapter 8. General discussion and clinical implications 
 
130 
on long-term adverse effects should be presented, incorrect attributions challenged, 
and patients should be offered personalized guidance during a discontinuation 
process. In what form this guidance should de presented, is beyond the scope of this 
thesis. We can imagine that for some patients cognitive behavioural therapy tailored at 
addressing maladaptive beliefs about withdrawal effects might be helpful. Others 
might benefit from mindfulness cognitive based therapy prior to discontinuation, as 
this had been demonstrated to be equally effective in preventing relapse/recurrence 
(48, 49). 
 
Recommendations for further research 
 
There seems to be a continuous flow of research on antidepressants: the development 
of new antidepressants (50), the demonstration of the (in) effectiveness of 
antidepressants (51, 52), the development of methods to keep patients taking the 
medication once prescribed (53). Interestingly, research on effectively withdrawing 
from antidepressants is scarce, let alone the difficulty to change inappropriate long-
term use of antidepressants. Considering the growing numbers of long-term users of 
antidepressant medication, further research into this is necessary and inevitable. Some 
examples of the many topics that need addressing in this area are why GPs prescribe 
antidepressant maintenance therapy, why they do not discontinue the use in the 
absence of an apparent indication, how to successfully discontinue long-term use of 
antidepressants and how to prevent relapse and/or restart of medication. 
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Samenvatting 
 
Dit proefschrift gaat over antidepressiva gebruik in de huisartsenpraktijk, in het 
bijzonder langdurig antidepressiva gebruik.  
 
Antidepressiva kunnen worden voorgeschreven bij een depressie of een angststoornis. 
In de afgelopen jaren is de visie op het gebruik van antidepressiva veranderd. Waar 
voorheen antidepressiva gebruik werd gestimuleerd en huisartsen werden bekritiseerd 
voor het onderbehandelen van depressies en angst- stoornissen, lijkt nu het tij 
gekeerd. De huidige NHG-standaard depressie pleit voor een terughoudend beleid in 
het voorschrijven van antidepressiva. In eerste instantie moet bij depressieve 
symptomen de patiënt voorgelicht worden en de symptomen vervolgd door middel 
van zogenoemde ‘watchful waiting’. Dit zou aangevuld kunnen worden door 
psychologische behandeling. Mocht er sprake zijn van ernstige symptomen of indien 
andere behandelingen geen baat geven, dan wordt het gebruik van antidepressiva 
geadviseerd. Na adequate respons, dient het antidepressivum 6-12 maanden 
gecontinueerd te worden. Chronisch gebruik wordt uitsluitend geadviseerd bij 
patiënten met recidiverende depressies of in het geval van aanwezigheid van 
risicofactoren op een terugval. Indien een antidepressivum onvoldoende effect heeft, 
dan adviseert de richtlijn om vervolg stappen te ondernemen, bijvoorbeeld dosering te 
verhogen, het middel of type antidepressivum te wijzigen en/of psychologische 
behandeling te starten. 
 
Het gebruik van antidepressiva is in het afgelopen decennia wereldwijd fors 
toegenomen, ook in Nederland. In de afgelopen 20 jaar zijn het aantal voorschriften 
van antidepressiva meer dan verdubbeld. De meeste mensen met psychische klachten 
worden door de huisarts behandeld; huisartsen zijn verantwoordelijk voor 80% van 
alle voorschriften antidepressiva. 
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De toename in voorschriften wordt vooral veroorzaakt door het langdurig gebruik van 
antidepressiva. Langdurig gebruik van antidepressiva kan terecht zijn, echter soms is er 
ook sprake van onterecht gebruik (volgens de huidige multidisciplinaire richtlijnen). Dit 
onterecht gebruik kan bestaan uit het onnodig continueren van antidepressiva zonder 
dat er nog een indicatie voor bestaat, zogenaamde overbehandeling, en uit 
zogenaamde onderbehandeling, waarbij er langdurig antidepressiva gebruikt wordt 
zonder dat dit (voldoende) effect heeft op de psychiatrische klachten van de patiënt. 
Met dit proefschrift hebben we geprobeerd om meer inzicht te verkrijgen in dit 
onterecht langdurig gebruik van antidepressiva.  
 
Door het uitvoeren van de PANDA studie hebben we getest of een eenvoudige 
interventie het onterecht langdurig gebruik van antidepressiva kon terugdringen. 
Hoofdstuk 2 belicht de opzet van het PANDA onderzoek, een cluster-gerandomiseerd 
gecontroleerde trial. Bij patiënten die 9 maanden of langer een antidepressivum 
gebruikten werd bekeken of zij dit middel (nog) terecht gebruikten, volgens de 
multidisciplinaire richtlijnen. Patiënten die onterecht chronisch antidepressiva 
gebruikten werden ingedeeld in twee groepen, afhankelijk van hun huidige 
ziektebeeld. Patiënten zonder een huidige psychiatrische ziekte werden ingedeeld in 
de groep overbehandeling en de patiënten waarbij er, ondanks het antidepressiva 
gebruik, sprake was van een huidige psychiatrische stoornis werden ingedeeld in de 
onderbehandeling groep. De deelnemende huisartsen werden gerandomiseerd, 
waarbij de huisarts of zijn gewone zorg moest geven of de interventie kreeg 
toebedeeld. Onze interventie bestond uit een brief aan de huisarts waarin werd 
beschreven in welke groep zijn/haar patiënt zich bevond en dus of er wel of niet 
sprake was van een huidige psychiatrische stoornis. Daarnaast werd in de brief een 
behandeladvies, conform de richtlijnen, gegeven welke was toegespitst op de 
desbetreffende patiënt. In het geval van overbehandeling bestond dit uit het advies te 
stoppen met de antidepressiva. Hierbij kreeg de huisarts informatie over het afbouwen 
van antidepressiva en mogelijke onttrekkingsverschijnselen. In het geval van 
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onderbehandeling kreeg de huisarts naast de huidige psychiatrische diagnose een 
uitgebreid behandeladvies, bestaande uit medicamenteuze en psychologische 
behandel opties.  
 
In hoofdstuk 3 worden de bevinden van het PANDA onderzoek besproken. We vonden 
een groot aantal potentieel onterecht langdurig antidepressiva gebruikers, maar 
slechts enkelen waren bereid deel te nemen aan onze studie. Met betrekking tot 
overbehandeling, hebben we laten zien dat het stoppen van antidepressiva erg lastig 
is. Ondanks het ontbreken van een huidige indicatie voor het doorgebruiken. Zowel 
huisartsen als patiënten waren huiverig om het advies om te stoppen aan te nemen, 
en als er een stoppoging werd ondernomen bleek het alsnog moeilijk om gestopt te 
blijven. Slechts enkelen bleken daadwerkelijk gestopt aan het einde van het onderzoek 
en dit getal was in de interventie groep even groot als in de controle groep. Wat wil 
zeggen dat onze interventie niet het beoogde doel van het verminderen van onterecht 
langdurig antidepressiva gebruik heeft weten te bereiken. Er bleken zelfs meer 
patiënten in de interventiegroep een terugval te krijgen in hun depressie of 
angststoornis dan in de controlegroep, maar opvallend genoeg was dit onafhankelijk 
van het wel/niet stoppen van de antidepressiva. 
 
Hiernaast vonden we slechts een klein aantal  die werden onderbehandeld, dat wil 
zeggen patiënten die ondanks chronisch gebruik van antidepressiva toch nog 
psychiatrische klachten hadden. Door dit kleine aantal, kunnen we weinig zeggen over 
het effect van de interventie. Wel was het opnieuw opvallend dat we een grote 
weerstand vonden tegen het gegeven behandeladvies. De helft van de patiënten 
hadden grote moeite om de behandeling te veranderen en een volgende stap te 
nemen naar een mogelijke remissie. 
 
Naast het effect op patiëntenniveau hebben we in hoofdstuk 4 ook gekeken of we met 
de interventie in de PANDA studie ook een kostenbesparing konden bewerkstelligen. 
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Hier hebben we gevonden dat het geven van een stopadvies bij patiënten die 
overbehandeld worden met langdurig antidepressiva gebruik resulteert in een kleine 
kostenreductie voor de samenleving. Vooral vonden we een vermindering in 
zogenaamde productiviteitsverliezen (kosten door arbeidsongeschiktheid en 
ziekteverlof). De kwaliteit van leven bleef hierbij gelijk. Zelfs al stopten de patiënten 
niet daadwerkelijk met hun antidepressivum, bleek er wel een verandering plaats te 
vinden waardoor de productiviteitsverliezen verminderden. We speculeren dat deze 
besparing mogelijk te maken heeft met een vermindering van stigma en patiënt 
empowerment verkregen door het stopadvies. 
 
In hoofdstuk 5 hebben we patiënten geïnterviewd over hun meningen over en hun 
ervaringen met (het stoppen van) langdurig antidepressiva gebruik. Door het 
analyseren van deze interviews konden de weerstand tegen het stoppen van de 
antidepressiva beter begrijpen. Patiënten vertelden dat zij hun antidepressivum nodig 
hadden, omdat zij een te kort hebben aan een stofje (serotonine) in hun hersenen. 
Ook was angst (voor terugval of het verstoren van het evenwicht) een belangrijk 
thema. Stoppogingen uit het verleden hadden deze angsten ook bekrachtigd, al waren 
deze pogingen vaak zonder begeleiding.  
 
Om ook de relatie tussen arts en patiënt in ogenschouw te kunnen nemen, hebben we 
een overzicht gemaakt van de bestaande instrumenten om deze relatie te meten 
(hoofdstuk 6). Een goede arts-patiënt relatie bevordert patiënt tevredenheid en ook 
het opvolgen van medische adviezen en ziekte uitkomsten. Het blijkt dat er veelvuldig 
wordt gesproken over de arts-patiënt relatie, terwijl er hiervoor nog geen duidelijk 
afgesproken definitie voor bestaat. Wij hebben 19 verschillende instrumenten 
gevonden die de arts-patiënt relatie meten, die een ieder een verschillend model of 
concept gebruikt. Een van de instrumenten, de PDRQ-9 werd in het PANDA onderzoek 
meegenomen. Helaas, door het kleine aantal patiënten dat daadwerkelijk succesvol 
stopten met hun antidepressivum was verdere analyse hiermee niet mogelijk. Het blijft 
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dus de vraag of de arts-patiënt relatie van invloed is op de uitkomsten van dit 
onderzoek. 
 
In hoofdstuk 7 worden de resultaten samengevat en ten slotte worden in hoofdstuk 8 
de belangrijkste bevindingen van dit proefschrift besproken. De belangrijkste 
methodologische beperkingen komen aan bod en de interpretatie van de resultaten 
worden bediscussieerd. Hieronder worden in het kort de discussiepunten neergezet. 
 
Als men een dogmatisch standpunt inneemt, laat dit proefschrift zien dat huisartsen 
moeite hebben met het opvolgen van hun eigen wetenschappelijk gevormde 
richtlijnen. De gevonden weerstand van de patiënten tegen de gegeven adviezen in de 
PANDA studie, zou geïnterpreteerd kunnen worden als een verschil in beoogd doel. 
Patiënten zien de noodzaak niet om iets te veranderen en hun huisartsen zijn geneigd 
hierin mee te gaan. Dit in tegenspraak met hun richtlijnen, de vraag is dan waarom 
gebeurt dit? Doen de huisartsen het verkeerd? Of is de richtlijn verkeerd? 
 
Het diagnosticeren van een depressie door de huisarts staat onder discussie. Ook hier 
heeft in het verleden de focus vooral op onderdiagnostiek gelegen. Instrumenten en 
vragenlijsten uit de psychiatrie werden naar de huisartsenpraktijken gehaald. Echter de 
zelfde set van symptomen zal in de huisartsenpraktijk een veel lager voorspellende 
waarde hebben voor een depressie dan in de psychiatrie, omdat de prevalentie veel 
lager is. Ook kunnen symptomen van een depressie overlappen met andere veel 
voorkomende ziekten en syndromen. Hiernaast is het voor een huisarts belangrijk om 
niet alle klachten te ‘medicaliseren’. Het wordt zelfs gesuggereerd dat het stellen van 
de diagnose depressie soms nadelige effecten kan hebben. Uit onderzoek blijkt dat 
huisartsen de voorkeur geven aan een multifactoriële uitleg van symptomen en 
context gericht behandelen.  
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De weg die antidepressiva hebben bewandeld lijkt niet nieuw. In het verleden zijn 
benzodiazepines met dezelfde grote enthousiasme ontvangen en wijd verspreid 
voorschreven. Later bleken deze middelen te veel te zijn voorgeschreven en moest het 
gebruik worden ingeperkt. Ook buiten de psychiatrie lijkt dit fenomeen vaker te 
gebeuren bij het introduceren van nieuwe geneesmiddelen. Hierbij schiet het 
enthousiasme soms door en is de druk voor huisartsen groot om deze middelen voor 
te schrijven. Pas later wordt er duidelijk welk effect dit overmatig voorschrijven heeft 
op bevolkingsniveau. Tegenwoordig lijken Nederlandse huisartsen wat conservatiever 
en voorzichtiger te zijn geworden in het omarmen van nieuwe geneesmiddelen. 
 
Het langdurig voorschrijven van antidepressiva zou heroverwogen moeten worden, 
ook gezien de lange termijn risico’s en effecten. De belofte ‘primum non nocere’ (eerst 
geen schade berokkenen) zou hierbij in het achterhoofd mee moeten spelen. De 
effectiviteit van antidepressiva staat reeds uitgebreid ter discussie. Daarnaast geven 
patiënten de voorkeur aan psychologische therapie boven medicatie. Indien patiënten 
toch antidepressiva krijgen, dan zou het continueren telkens opnieuw beoordeeld 
moeten worden.  
 
We kunnen dus concluderen dat het veranderen van beleid bij patiënten die onterecht 
langdurig antidepressiva gebruiken, moeizaam gaat. Na eerst overtuigd te moeten 
worden van het goeds van antidepressiva, worden huisartsen en patiënten nu opnieuw 
gevraagd om te veranderen. Dit gaat niet zonder slag of stoot. 
 
Adviezen voor de praktijk: 
- Het anticiperen op een gelimiteerd gebruik van antidepressiva, faciliteert een 
toekomstige stoppoging. 
- De werking van antidepressiva als een te kort aan serotonine welke aangevuld 
moet worden, wordt door patiënten gezien als argument voor chronisch 
gebruik. 
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- Striktere controle van herhaalrecepten van antidepressiva zou onterecht 
langdurig gebruik kunnen voorkomen 
- Patiënten kunnen onjuiste ideeën hebben over hun antidepressiva gebruik, 
welke een succesvolle stoppoging in de weg kunnen staan. 
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